www.tyc66.com_www.tyc66.com-【会员注册】:科创板首份三季报出炉铂力特前9月净利增近两倍

www.tyc66.com_www.tyc66.com-【会员注册】

2019-11-15 11:12:48

字体:标准

  In2016,MSDcelebratedits125thanniversaryasaglobalhealthcareleader.Wecreatedthispageasacelebrationofouraccomplishmentsaswellastohighlightwhatwe'reexcitedaboutfortheyearstocome.Thisisanexcitingtimeforourcompanyandtheworld.Today,weareattheforefrontofinventingtoolsforthefightagainstsomeoftheworld’smosturgentglobalhealthchallenges.Thisincludesmorethan30differentcancers,hepatitisC,Alzheimer’sdisease,Ebola,antibiotic-resistantsuperbugs,cardio-metabolicdiseases,andmanyothers.AfyaSerengetiProjectFormorethan15years,haspartneredwiththe(Afyameans"health"inSwahili)intheSerengetiregionofTanzaniaineasternAfrica.Wehelpprovideaccesstopreventivecare,includingrabiesvaccinationsforlocaldogs.Todate,wehavedonatedtwomillionrabiesvaccinestosupportprogramsinIndia,Malawi,SriLanka,TanzaniaandUganda.Wealsoprovidetoolssuchasall-terrainvehiclesandtentstohelpmakesuretheprojectisabletoreachthemostremotecornersoftheregion.Rabiesinhumansanddomesticanimalshasnowbeenvirtuallyeliminatedfromthisareaandhumanhospitalizationsduetorabiddogbiteshavedecreased92percent.“EventhoughDr.Alzheimercharacterizedthediseasein1906,itwasn’tuntilthelastfewdecadesthatthediseasebecamerecognizedasarealillnessseparatefromnormalagingandotherformsofdementia,”saidDarryleSchoepp,Ph.D.,vicepresidentandtherapeuticareahead,Neuroscience,MSD.“Nowpeoplearelivinglonger,andwecanseehowthediseaseworks,”saidDavidMichelson,M.D.,vicepresident,ClinicalNeuroscienceResearch,MSD.“Scienceisataplacewherenotonlydoweunderstandmoreaboutit,butweareexploringwaystodosomethingaboutit.”“Newtechnologiesareallowingtheidentificationofearlydiseasesignswhichwehopewillallowustointervenepromptlyinordertosloworhaltprogression.That’stheholygrail.Whatyouwanttodoistohavesomethingthatworksandtobeabletouseitbeforethediseaserobspeopleofwhotheyreallyare,”saidDr.Michelson.

  Overthepast125years,we’veseentheworldchangethroughthepowerofmedicineandinvention.Whileeachpivotalmilestonehasbeenunique,onethingtheyhaveincommonisthatwehaven’tdoneitalone.AtMSD,wehavealwaysbelievedthatgreatmedicalbreakthroughsrelyonteamwork–fromwithinandoutsideofMSD–andourhistoryhasprovenit.Weareproudtohaveworkedinpartnershipwithcompanies,academics,governments,patientorganizations,healthcareprofessionals,nongovernmentalorganizations(NGOs),multilateralorganizationsandothersintheprivatesector--tohelpimprovelivesaroundtheworldandcontinuetosolvesomeoftheworld’smostseriousillnesses.Intheearly1990s,HedyTepplerwastreatingAIDSpatientswithHIV/AIDSatahospitalinPhiladelphia.ShewasalsoservingasaclinicaltrialinvestigatorforPhase1and2MSDstudiesofanewclassofanti-HIVdrugsdesignedtoblocktheHIVproteaseenzymeandthuspreventHIVreplication."Theearlyresultswereexciting.Inashorttime,manypatientsrespondedtotheinvestigationaltreatment,"saysHedy.HerpositiveexperienceduringtheseandsubsequentclinicaltrialswaslargelywhyshejoinedMSDin1996."Iwantedtobemoreinvolvedindrugdevelopmentandclinicaltrialdesign,andMSDwasdoingsomegroundbreakingworkinHIV,"saysHedy,whonowservesasexecutivedirector,ClinicalResearch,InfectiousDiseases,atMSDResearchLaboratories.TheyearbeforeHedyarrived,anotherprominentHIVresearcherandthoughtleaderwaskeepingaclosewatchonMSD'swork.Bach-YenNguyen,nowretired-executivedirector,sectionhead,HCVandHIV,decidedtoleavetheNationalInstitutesofHealthtoworkonMSD'sHIVresearchdevelopmentteam.Bach-YenhadspentyearstreatingAIDSpatientsandworkinginHIVresearchandsawgreatpotentialinMSD'swork."WewerefacedwithanopportunitytohelppatientsinfectedwithHIV."ForBach-Yen,whoalsomadevitalcontributionstothedevelopmentofanotheroneofMSD'smedicinesforthetreatmentofHIV,thedrug'sapprovalcontinuestobehermostmemorablemomentatMSD."Weworkedlonghours.ThereweretimeswhenIcouldn'tattendschooleventswithmyson.WhenpeopleaskedhimwhereIwas,hewouldsay,'MomisbusyhelpingpeoplewithAIDS.'Hewasonly12,butheunderstoodtheimportanceofthework."Withinafewyears,theteamachievedadditionalsuccess:In2011,theFDAapprovedachewabletabletformofthisfirstagentinanewclassofanti-HIVagentsforchildren2yearsandolder,andin2013,approvedgranulesfororalsuspensionforinfants4weeksandolder."Ourpediatricsprogramhasbeenextremelysatisfyingasthereisatremendousneedfornewanti-HIVagentsthatcanbeusedacrosstheentirepediatricagerange,"saysHedy,wholeadstheIsentresspediatricdevelopmentprogram.In1987,MSD’sthenCEODr.P.RoyVagelosannounced,inanunprecedentedactofglobalhealthcareleadership,thatMSDwoulddonateivermectin–asmuchasneededforaslongasneeded–withthegoaltohelpeliminateriverblindness.MSDrecognizedinordertoreachthisgoal,manyorganizationswithuniqueskillswouldneedtoworktogetherasateam.Asaresult,MSDcreatedtheMectizanDonationProgram(MDP).OperatingfromtheAtlanta-basedTaskForceforGlobalHealth,theMDPcoordinatesactivitiesbetweenMSD,WHO,theWorldBankandarangeofpublicandprivatestakeholders.In1998,MSDexpandeditscommitmentfromtheMectizanDonationProgramtoincludedonatingivermectinforanotherdisease,lymphaticfilariasis(LF),alsoknownaselephantiasis,inAfricancountriesandYemenwhereitco-existswithriverblindness.ForLF,ivermectinisadministeredwithalbendazole,adrugdonatedbyGSK.

  In2016,MSDcelebratedits125thanniversaryasaglobalhealthcareleader.Wecreatedthispageasacelebrationofouraccomplishmentsaswellastohighlightwhatwe'reexcitedaboutfortheyearstocome.Thisisanexcitingtimeforourcompanyandtheworld.Today,weareattheforefrontofinventingtoolsforthefightagainstsomeoftheworld’smosturgentglobalhealthchallenges.Thisincludesmorethan30differentcancers,hepatitisC,Alzheimer’sdisease,Ebola,antibiotic-resistantsuperbugs,cardio-metabolicdiseases,andmanyothers.“EventhoughDr.Alzheimercharacterizedthediseasein1906,itwasn’tuntilthelastfewdecadesthatthediseasebecamerecognizedasarealillnessseparatefromnormalagingandotherformsofdementia,”saidDarryleSchoepp,Ph.D.,vicepresidentandtherapeuticareahead,Neuroscience,MSD.“Nowpeoplearelivinglonger,andwecanseehowthediseaseworks,”saidDavidMichelson,M.D.,vicepresident,ClinicalNeuroscienceResearch,MSD.“Scienceisataplacewherenotonlydoweunderstandmoreaboutit,butweareexploringwaystodosomethingaboutit.”“Newtechnologiesareallowingtheidentificationofearlydiseasesignswhichwehopewillallowustointervenepromptlyinordertosloworhaltprogression.That’stheholygrail.Whatyouwanttodoistohavesomethingthatworksandtobeabletouseitbeforethediseaserobspeopleofwhotheyreallyare,”saidDr.Michelson.HbA1c,ameasureoftheaveragelevelofbloodsugaroverthepasttwotothreemonths,helpsyouandyourdoctorseehowwellyourdiabetestreatmentplanisworking.TherecommendedHbA1c,goalformanyadultswithtype2diabetesislessthan7%;however,thismayvarydependingontheindividual.Highbloodsugarlevelsovertimecanputpeoplewithdiabetesatriskofmanyserioushealthproblems,suchasheartdisease,stroke,kidneydisease,blindnessandnerveproblems.That’swhyitisimportantforpeoplelivingwithdiabetestoworkwiththeirdoctortosetindividualizedgoalsanddevelopapersonalizeddiabetesmanagementplantomanagetheABCsofdiabetes:AforHbA1c,BforbloodpressureandCforcholesterol.

  Ourdiscoveryscientists“strivetomaketheimpossiblepossible,”saysJoeMiletich.Andheshouldknow:AstheseniorvicepresidentofDiscoveryPreclinicalandEarlyDevelopment,heleadsateamofresearcherswhoarechargedwithmakingthings“possiblethatweren’tpossiblebefore.”Hecontinues:“Webelievedrugdiscoveryisfoundationalforustocontinuebringingcriticalmedicinestotheworld.”About14,500peopleareinvolvedinscientificresearchatMSD.OurRDcolleaguesarealltaskedwiththesamemission:tosolvethepuzzlesofhumandiseasebiologyandthentranslatethosefindingsintonewtherapiesforpatients.Theyaredriventopushtheboundariesofscienceandtothentransformtheirdiscoveriesintomeaningfulnewtherapeutics.In2016,MSDcelebratedits125thanniversaryasaglobalhealthcareleader.Wecreatedthispageasacelebrationofouraccomplishmentsaswellastohighlightwhatwe'reexcitedaboutfortheyearstocome.Thisisanexcitingtimeforourcompanyandtheworld.Today,weareattheforefrontofinventingtoolsforthefightagainstsomeoftheworld’smosturgentglobalhealthchallenges.Thisincludesmorethan30differentcancers,hepatitisC,Alzheimer’sdisease,Ebola,antibiotic-resistantsuperbugs,cardio-metabolicdiseases,andmanyothers.Intheearly1990s,HedyTepplerwastreatingAIDSpatientswithHIV/AIDSatahospitalinPhiladelphia.ShewasalsoservingasaclinicaltrialinvestigatorforPhase1and2MSDstudiesofanewclassofanti-HIVdrugsdesignedtoblocktheHIVproteaseenzymeandthuspreventHIVreplication."Theearlyresultswereexciting.Inashorttime,manypatientsrespondedtotheinvestigationaltreatment,"saysHedy.HerpositiveexperienceduringtheseandsubsequentclinicaltrialswaslargelywhyshejoinedMSDin1996."Iwantedtobemoreinvolvedindrugdevelopmentandclinicaltrialdesign,andMSDwasdoingsomegroundbreakingworkinHIV,"saysHedy,whonowservesasexecutivedirector,ClinicalResearch,InfectiousDiseases,atMSDResearchLaboratories.TheyearbeforeHedyarrived,anotherprominentHIVresearcherandthoughtleaderwaskeepingaclosewatchonMSD'swork.Bach-YenNguyen,nowretired-executivedirector,sectionhead,HCVandHIV,decidedtoleavetheNationalInstitutesofHealthtoworkonMSD'sHIVresearchdevelopmentteam.Bach-YenhadspentyearstreatingAIDSpatientsandworkinginHIVresearchandsawgreatpotentialinMSD'swork."WewerefacedwithanopportunitytohelppatientsinfectedwithHIV."ForBach-Yen,whoalsomadevitalcontributionstothedevelopmentofanotheroneofMSD'smedicinesforthetreatmentofHIV,thedrug'sapprovalcontinuestobehermostmemorablemomentatMSD."Weworkedlonghours.ThereweretimeswhenIcouldn'tattendschooleventswithmyson.WhenpeopleaskedhimwhereIwas,hewouldsay,'MomisbusyhelpingpeoplewithAIDS.'Hewasonly12,butheunderstoodtheimportanceofthework."Withinafewyears,theteamachievedadditionalsuccess:In2011,theFDAapprovedachewabletabletformofthisfirstagentinanewclassofanti-HIVagentsforchildren2yearsandolder,andin2013,approvedgranulesfororalsuspensionforinfants4weeksandolder."Ourpediatricsprogramhasbeenextremelysatisfyingasthereisatremendousneedfornewanti-HIVagentsthatcanbeusedacrosstheentirepediatricagerange,"saysHedy,wholeadstheIsentresspediatricdevelopmentprogram.

  In1987,MSD’sthenCEODr.P.RoyVagelosannounced,inanunprecedentedactofglobalhealthcareleadership,thatMSDwoulddonateivermectin–asmuchasneededforaslongasneeded–withthegoaltohelpeliminateriverblindness.MSDrecognizedinordertoreachthisgoal,manyorganizationswithuniqueskillswouldneedtoworktogetherasateam.Asaresult,MSDcreatedtheMectizanDonationProgram(MDP).OperatingfromtheAtlanta-basedTaskForceforGlobalHealth,theMDPcoordinatesactivitiesbetweenMSD,WHO,theWorldBankandarangeofpublicandprivatestakeholders.In1998,MSDexpandeditscommitmentfromtheMectizanDonationProgramtoincludedonatingivermectinforanotherdisease,lymphaticfilariasis(LF),alsoknownaselephantiasis,inAfricancountriesandYemenwhereitco-existswithriverblindness.ForLF,ivermectinisadministeredwithalbendazole,adrugdonatedbyGSK.In1987,MSD’sthenCEODr.P.RoyVagelosannounced,inanunprecedentedactofglobalhealthcareleadership,thatMSDwoulddonateivermectin–asmuchasneededforaslongasneeded–withthegoaltohelpeliminateriverblindness.MSDrecognizedinordertoreachthisgoal,manyorganizationswithuniqueskillswouldneedtoworktogetherasateam.Asaresult,MSDcreatedtheMectizanDonationProgram(MDP).OperatingfromtheAtlanta-basedTaskForceforGlobalHealth,theMDPcoordinatesactivitiesbetweenMSD,WHO,theWorldBankandarangeofpublicandprivatestakeholders.In1998,MSDexpandeditscommitmentfromtheMectizanDonationProgramtoincludedonatingivermectinforanotherdisease,lymphaticfilariasis(LF),alsoknownaselephantiasis,inAfricancountriesandYemenwhereitco-existswithriverblindness.ForLF,ivermectinisadministeredwithalbendazole,adrugdonatedbyGSK.Ourdiscoveryscientists“strivetomaketheimpossiblepossible,”saysJoeMiletich.Andheshouldknow:AstheseniorvicepresidentofDiscoveryPreclinicalandEarlyDevelopment,heleadsateamofresearcherswhoarechargedwithmakingthings“possiblethatweren’tpossiblebefore.”Hecontinues:“Webelievedrugdiscoveryisfoundationalforustocontinuebringingcriticalmedicinestotheworld.”About14,500peopleareinvolvedinscientificresearchatMSD.OurRDcolleaguesarealltaskedwiththesamemission:tosolvethepuzzlesofhumandiseasebiologyandthentranslatethosefindingsintonewtherapiesforpatients.Theyaredriventopushtheboundariesofscienceandtothentransformtheirdiscoveriesintomeaningfulnewtherapeutics.

  HbA1c,ameasureoftheaveragelevelofbloodsugaroverthepasttwotothreemonths,helpsyouandyourdoctorseehowwellyourdiabetestreatmentplanisworking.TherecommendedHbA1c,goalformanyadultswithtype2diabetesislessthan7%;however,thismayvarydependingontheindividual.Highbloodsugarlevelsovertimecanputpeoplewithdiabetesatriskofmanyserioushealthproblems,suchasheartdisease,stroke,kidneydisease,blindnessandnerveproblems.That’swhyitisimportantforpeoplelivingwithdiabetestoworkwiththeirdoctortosetindividualizedgoalsanddevelopapersonalizeddiabetesmanagementplantomanagetheABCsofdiabetes:AforHbA1c,BforbloodpressureandCforcholesterol.In1987,MSD’sthenCEODr.P.RoyVagelosannounced,inanunprecedentedactofglobalhealthcareleadership,thatMSDwoulddonateivermectin–asmuchasneededforaslongasneeded–withthegoaltohelpeliminateriverblindness.MSDrecognizedinordertoreachthisgoal,manyorganizationswithuniqueskillswouldneedtoworktogetherasateam.Asaresult,MSDcreatedtheMectizanDonationProgram(MDP).OperatingfromtheAtlanta-basedTaskForceforGlobalHealth,theMDPcoordinatesactivitiesbetweenMSD,WHO,theWorldBankandarangeofpublicandprivatestakeholders.In1998,MSDexpandeditscommitmentfromtheMectizanDonationProgramtoincludedonatingivermectinforanotherdisease,lymphaticfilariasis(LF),alsoknownaselephantiasis,inAfricancountriesandYemenwhereitco-existswithriverblindness.ForLF,ivermectinisadministeredwithalbendazole,adrugdonatedbyGSK.In1987,MSD’sthenCEODr.P.RoyVagelosannounced,inanunprecedentedactofglobalhealthcareleadership,thatMSDwoulddonateivermectin–asmuchasneededforaslongasneeded–withthegoaltohelpeliminateriverblindness.MSDrecognizedinordertoreachthisgoal,manyorganizationswithuniqueskillswouldneedtoworktogetherasateam.Asaresult,MSDcreatedtheMectizanDonationProgram(MDP).OperatingfromtheAtlanta-basedTaskForceforGlobalHealth,theMDPcoordinatesactivitiesbetweenMSD,WHO,theWorldBankandarangeofpublicandprivatestakeholders.In1998,MSDexpandeditscommitmentfromtheMectizanDonationProgramtoincludedonatingivermectinforanotherdisease,lymphaticfilariasis(LF),alsoknownaselephantiasis,inAfricancountriesandYemenwhereitco-existswithriverblindness.ForLF,ivermectinisadministeredwithalbendazole,adrugdonatedbyGSK.

  TheMSDFellowshipforGlobalHealthisonewayMSDishelpinganswertheglobalhealthneedsoftheunderserved.MSDemployeeswhoparticipateintheprogramarecalledRichardT.ClarkFellows(RTCFellows)inhonorofretiredChairmanandCEORichardT.Clarkandhisphilosophyofpassion,purposeandcommitmenttocorporateresponsibility.Launchedin2012,theprogramoffersMSDemployeesopportunitiestosharetheirskillswithpeoplearoundtheworld.Asmanyas30Fellowsareselectedeachyear;theexpertiseoftheapplicantsismatchedtotheneedsofthepartnerorganizations.Duringthethree-monthassignments,theFellowsareembeddedwithinanon-profitorganizationinthefield.Intheearly1990s,HedyTepplerwastreatingAIDSpatientswithHIV/AIDSatahospitalinPhiladelphia.ShewasalsoservingasaclinicaltrialinvestigatorforPhase1and2MSDstudiesofanewclassofanti-HIVdrugsdesignedtoblocktheHIVproteaseenzymeandthuspreventHIVreplication."Theearlyresultswereexciting.Inashorttime,manypatientsrespondedtotheinvestigationaltreatment,"saysHedy.HerpositiveexperienceduringtheseandsubsequentclinicaltrialswaslargelywhyshejoinedMSDin1996."Iwantedtobemoreinvolvedindrugdevelopmentandclinicaltrialdesign,andMSDwasdoingsomegroundbreakingworkinHIV,"saysHedy,whonowservesasexecutivedirector,ClinicalResearch,InfectiousDiseases,atMSDResearchLaboratories.TheyearbeforeHedyarrived,anotherprominentHIVresearcherandthoughtleaderwaskeepingaclosewatchonMSD'swork.Bach-YenNguyen,nowretired-executivedirector,sectionhead,HCVandHIV,decidedtoleavetheNationalInstitutesofHealthtoworkonMSD'sHIVresearchdevelopmentteam.Bach-YenhadspentyearstreatingAIDSpatientsandworkinginHIVresearchandsawgreatpotentialinMSD'swork."WewerefacedwithanopportunitytohelppatientsinfectedwithHIV."ForBach-Yen,whoalsomadevitalcontributionstothedevelopmentofanotheroneofMSD'smedicinesforthetreatmentofHIV,thedrug'sapprovalcontinuestobehermostmemorablemomentatMSD."Weworkedlonghours.ThereweretimeswhenIcouldn'tattendschooleventswithmyson.WhenpeopleaskedhimwhereIwas,hewouldsay,'MomisbusyhelpingpeoplewithAIDS.'Hewasonly12,butheunderstoodtheimportanceofthework."Withinafewyears,theteamachievedadditionalsuccess:In2011,theFDAapprovedachewabletabletformofthisfirstagentinanewclassofanti-HIVagentsforchildren2yearsandolder,andin2013,approvedgranulesfororalsuspensionforinfants4weeksandolder."Ourpediatricsprogramhasbeenextremelysatisfyingasthereisatremendousneedfornewanti-HIVagentsthatcanbeusedacrosstheentirepediatricagerange,"saysHedy,wholeadstheIsentresspediatricdevelopmentprogram.Overthepast125years,we’veseentheworldchangethroughthepowerofmedicineandinvention.Whileeachpivotalmilestonehasbeenunique,onethingtheyhaveincommonisthatwehaven’tdoneitalone.AtMSD,wehavealwaysbelievedthatgreatmedicalbreakthroughsrelyonteamwork–fromwithinandoutsideofMSD–andourhistoryhasprovenit.Weareproudtohaveworkedinpartnershipwithcompanies,academics,governments,patientorganizations,healthcareprofessionals,nongovernmentalorganizations(NGOs),multilateralorganizationsandothersintheprivatesector--tohelpimprovelivesaroundtheworldandcontinuetosolvesomeoftheworld’smostseriousillnesses.

  HbA1c,ameasureoftheaveragelevelofbloodsugaroverthepasttwotothreemonths,helpsyouandyourdoctorseehowwellyourdiabetestreatmentplanisworking.TherecommendedHbA1c,goalformanyadultswithtype2diabetesislessthan7%;however,thismayvarydependingontheindividual.Highbloodsugarlevelsovertimecanputpeoplewithdiabetesatriskofmanyserioushealthproblems,suchasheartdisease,stroke,kidneydisease,blindnessandnerveproblems.That’swhyitisimportantforpeoplelivingwithdiabetestoworkwiththeirdoctortosetindividualizedgoalsanddevelopapersonalizeddiabetesmanagementplantomanagetheABCsofdiabetes:AforHbA1c,BforbloodpressureandCforcholesterol.Ourdiscoveryscientists“strivetomaketheimpossiblepossible,”saysJoeMiletich.Andheshouldknow:AstheseniorvicepresidentofDiscoveryPreclinicalandEarlyDevelopment,heleadsateamofresearcherswhoarechargedwithmakingthings“possiblethatweren’tpossiblebefore.”Hecontinues:“Webelievedrugdiscoveryisfoundationalforustocontinuebringingcriticalmedicinestotheworld.”About14,500peopleareinvolvedinscientificresearchatMSD.OurRDcolleaguesarealltaskedwiththesamemission:tosolvethepuzzlesofhumandiseasebiologyandthentranslatethosefindingsintonewtherapiesforpatients.Theyaredriventopushtheboundariesofscienceandtothentransformtheirdiscoveriesintomeaningfulnewtherapeutics.AfyaSerengetiProjectFormorethan15years,haspartneredwiththe(Afyameans"health"inSwahili)intheSerengetiregionofTanzaniaineasternAfrica.Wehelpprovideaccesstopreventivecare,includingrabiesvaccinationsforlocaldogs.Todate,wehavedonatedtwomillionrabiesvaccinestosupportprogramsinIndia,Malawi,SriLanka,TanzaniaandUganda.Wealsoprovidetoolssuchasall-terrainvehiclesandtentstohelpmakesuretheprojectisabletoreachthemostremotecornersoftheregion.Rabiesinhumansanddomesticanimalshasnowbeenvirtuallyeliminatedfromthisareaandhumanhospitalizationsduetorabiddogbiteshavedecreased92percent.

  In2016,MSDcelebratedits125thanniversaryasaglobalhealthcareleader.Wecreatedthispageasacelebrationofouraccomplishmentsaswellastohighlightwhatwe'reexcitedaboutfortheyearstocome.Thisisanexcitingtimeforourcompanyandtheworld.Today,weareattheforefrontofinventingtoolsforthefightagainstsomeoftheworld’smosturgentglobalhealthchallenges.Thisincludesmorethan30differentcancers,hepatitisC,Alzheimer’sdisease,Ebola,antibiotic-resistantsuperbugs,cardio-metabolicdiseases,andmanyothers.ELIAV:HCV[hepatitisCvirus]infectionisablood-bornedisease.Peoplebecomeinfectedwhenexposedtocontaminatedbloodproductsorcontaminatedsyringesorinjectionequipment.TheincidenceofHCVinfection(thenknownasnon-A/non-Bhepatitis)priorto1965waslow;however,therateincreasedsteadilyintothe1980s.In1988,HCVwasidentifiedandbloodsupplyscreeningforHCVbecameavailablein1992.Peoplegotinfectedandusuallydidn'tknowitbecausetheacuteinfectionistypicallyasymptomatic.Afterprolongedinfection,20to25years,orso,peoplewerepresentingwithadvancedliverdamage,whichcanleadtocirrhosisandeventuallyevenliverfailureorlivercancer.Ahugecohortofbabyboomersgotinfected,didn'tknowit,aregraduallygettingdiagnosedandfindingtheirdiseaseissoadvancedthattheyareapproachingacrisispoint.Theclockistickingonthisproblem.Antibioticshaverevolutionizedmedicineinmanyrespects,andcountlessliveshavebeensaved;theirdiscoverywasaturningpointinhumanhistory.Foralmostacentury,bacteria-fightingdrugsknownasantibioticshavehelpedtomanagemanyoftheharmfulbacteriathatcanmakeussick.Butinrecentdecades,theyhavebecomelesseffectiveagainstsometypesofbacteria.Currently,certainbacteriaarenowunbeatablewithtoday’smedicines.Unfortunately,newdrug-resistant“superbugs”haveemerged,whicharestrainsofbacteriathatareresistanttoseveraltypesofantibiotics.Infact,theWorldHealthOrganizationhasclassifiedthisas“aseriousthreat[that]isnolongerapredictionforthefuture,itishappeningrightnowineveryregionoftheworldandhasthepotentialtoaffectanyone,ofanyage,inanycountry.”

  Overthepast125years,we’veseentheworldchangethroughthepowerofmedicineandinvention.Whileeachpivotalmilestonehasbeenunique,onethingtheyhaveincommonisthatwehaven’tdoneitalone.AtMSD,wehavealwaysbelievedthatgreatmedicalbreakthroughsrelyonteamwork–fromwithinandoutsideofMSD–andourhistoryhasprovenit.Weareproudtohaveworkedinpartnershipwithcompanies,academics,governments,patientorganizations,healthcareprofessionals,nongovernmentalorganizations(NGOs),multilateralorganizationsandothersintheprivatesector--tohelpimprovelivesaroundtheworldandcontinuetosolvesomeoftheworld’smostseriousillnesses.“EventhoughDr.Alzheimercharacterizedthediseasein1906,itwasn’tuntilthelastfewdecadesthatthediseasebecamerecognizedasarealillnessseparatefromnormalagingandotherformsofdementia,”saidDarryleSchoepp,Ph.D.,vicepresidentandtherapeuticareahead,Neuroscience,MSD.“Nowpeoplearelivinglonger,andwecanseehowthediseaseworks,”saidDavidMichelson,M.D.,vicepresident,ClinicalNeuroscienceResearch,MSD.“Scienceisataplacewherenotonlydoweunderstandmoreaboutit,butweareexploringwaystodosomethingaboutit.”“Newtechnologiesareallowingtheidentificationofearlydiseasesignswhichwehopewillallowustointervenepromptlyinordertosloworhaltprogression.That’stheholygrail.Whatyouwanttodoistohavesomethingthatworksandtobeabletouseitbeforethediseaserobspeopleofwhotheyreallyare,”saidDr.Michelson.Ourdiscoveryscientists“strivetomaketheimpossiblepossible,”saysJoeMiletich.Andheshouldknow:AstheseniorvicepresidentofDiscoveryPreclinicalandEarlyDevelopment,heleadsateamofresearcherswhoarechargedwithmakingthings“possiblethatweren’tpossiblebefore.”Hecontinues:“Webelievedrugdiscoveryisfoundationalforustocontinuebringingcriticalmedicinestotheworld.”About14,500peopleareinvolvedinscientificresearchatMSD.OurRDcolleaguesarealltaskedwiththesamemission:tosolvethepuzzlesofhumandiseasebiologyandthentranslatethosefindingsintonewtherapiesforpatients.Theyaredriventopushtheboundariesofscienceandtothentransformtheirdiscoveriesintomeaningfulnewtherapeutics.

  ELIAV:HCV[hepatitisCvirus]infectionisablood-bornedisease.Peoplebecomeinfectedwhenexposedtocontaminatedbloodproductsorcontaminatedsyringesorinjectionequipment.TheincidenceofHCVinfection(thenknownasnon-A/non-Bhepatitis)priorto1965waslow;however,therateincreasedsteadilyintothe1980s.In1988,HCVwasidentifiedandbloodsupplyscreeningforHCVbecameavailablein1992.Peoplegotinfectedandusuallydidn'tknowitbecausetheacuteinfectionistypicallyasymptomatic.Afterprolongedinfection,20to25years,orso,peoplewerepresentingwithadvancedliverdamage,whichcanleadtocirrhosisandeventuallyevenliverfailureorlivercancer.Ahugecohortofbabyboomersgotinfected,didn'tknowit,aregraduallygettingdiagnosedandfindingtheirdiseaseissoadvancedthattheyareapproachingacrisispoint.Theclockistickingonthisproblem.TheMSDFellowshipforGlobalHealthisonewayMSDishelpinganswertheglobalhealthneedsoftheunderserved.MSDemployeeswhoparticipateintheprogramarecalledRichardT.ClarkFellows(RTCFellows)inhonorofretiredChairmanandCEORichardT.Clarkandhisphilosophyofpassion,purposeandcommitmenttocorporateresponsibility.Launchedin2012,theprogramoffersMSDemployeesopportunitiestosharetheirskillswithpeoplearoundtheworld.Asmanyas30Fellowsareselectedeachyear;theexpertiseoftheapplicantsismatchedtotheneedsofthepartnerorganizations.Duringthethree-monthassignments,theFellowsareembeddedwithinanon-profitorganizationinthefield.ELIAV:HCV[hepatitisCvirus]infectionisablood-bornedisease.Peoplebecomeinfectedwhenexposedtocontaminatedbloodproductsorcontaminatedsyringesorinjectionequipment.TheincidenceofHCVinfection(thenknownasnon-A/non-Bhepatitis)priorto1965waslow;however,therateincreasedsteadilyintothe1980s.In1988,HCVwasidentifiedandbloodsupplyscreeningforHCVbecameavailablein1992.Peoplegotinfectedandusuallydidn'tknowitbecausetheacuteinfectionistypicallyasymptomatic.Afterprolongedinfection,20to25years,orso,peoplewerepresentingwithadvancedliverdamage,whichcanleadtocirrhosisandeventuallyevenliverfailureorlivercancer.Ahugecohortofbabyboomersgotinfected,didn'tknowit,aregraduallygettingdiagnosedandfindingtheirdiseaseissoadvancedthattheyareapproachingacrisispoint.Theclockistickingonthisproblem.

  ELIAV:HCV[hepatitisCvirus]infectionisablood-bornedisease.Peoplebecomeinfectedwhenexposedtocontaminatedbloodproductsorcontaminatedsyringesorinjectionequipment.TheincidenceofHCVinfection(thenknownasnon-A/non-Bhepatitis)priorto1965waslow;however,therateincreasedsteadilyintothe1980s.In1988,HCVwasidentifiedandbloodsupplyscreeningforHCVbecameavailablein1992.Peoplegotinfectedandusuallydidn'tknowitbecausetheacuteinfectionistypicallyasymptomatic.Afterprolongedinfection,20to25years,orso,peoplewerepresentingwithadvancedliverdamage,whichcanleadtocirrhosisandeventuallyevenliverfailureorlivercancer.Ahugecohortofbabyboomersgotinfected,didn'tknowit,aregraduallygettingdiagnosedandfindingtheirdiseaseissoadvancedthattheyareapproachingacrisispoint.Theclockistickingonthisproblem.ELIAV:HCV[hepatitisCvirus]infectionisablood-bornedisease.Peoplebecomeinfectedwhenexposedtocontaminatedbloodproductsorcontaminatedsyringesorinjectionequipment.TheincidenceofHCVinfection(thenknownasnon-A/non-Bhepatitis)priorto1965waslow;however,therateincreasedsteadilyintothe1980s.In1988,HCVwasidentifiedandbloodsupplyscreeningforHCVbecameavailablein1992.Peoplegotinfectedandusuallydidn'tknowitbecausetheacuteinfectionistypicallyasymptomatic.Afterprolongedinfection,20to25years,orso,peoplewerepresentingwithadvancedliverdamage,whichcanleadtocirrhosisandeventuallyevenliverfailureorlivercancer.Ahugecohortofbabyboomersgotinfected,didn'tknowit,aregraduallygettingdiagnosedandfindingtheirdiseaseissoadvancedthattheyareapproachingacrisispoint.Theclockistickingonthisproblem.In1987,MSD’sthenCEODr.P.RoyVagelosannounced,inanunprecedentedactofglobalhealthcareleadership,thatMSDwoulddonateivermectin–asmuchasneededforaslongasneeded–withthegoaltohelpeliminateriverblindness.MSDrecognizedinordertoreachthisgoal,manyorganizationswithuniqueskillswouldneedtoworktogetherasateam.Asaresult,MSDcreatedtheMectizanDonationProgram(MDP).OperatingfromtheAtlanta-basedTaskForceforGlobalHealth,theMDPcoordinatesactivitiesbetweenMSD,WHO,theWorldBankandarangeofpublicandprivatestakeholders.In1998,MSDexpandeditscommitmentfromtheMectizanDonationProgramtoincludedonatingivermectinforanotherdisease,lymphaticfilariasis(LF),alsoknownaselephantiasis,inAfricancountriesandYemenwhereitco-existswithriverblindness.ForLF,ivermectinisadministeredwithalbendazole,adrugdonatedbyGSK.

  Overthepast125years,we’veseentheworldchangethroughthepowerofmedicineandinvention.Whileeachpivotalmilestonehasbeenunique,onethingtheyhaveincommonisthatwehaven’tdoneitalone.AtMSD,wehavealwaysbelievedthatgreatmedicalbreakthroughsrelyonteamwork–fromwithinandoutsideofMSD–andourhistoryhasprovenit.Weareproudtohaveworkedinpartnershipwithcompanies,academics,governments,patientorganizations,healthcareprofessionals,nongovernmentalorganizations(NGOs),multilateralorganizationsandothersintheprivatesector--tohelpimprovelivesaroundtheworldandcontinuetosolvesomeoftheworld’smostseriousillnesses.Intheearly1990s,HedyTepplerwastreatingAIDSpatientswithHIV/AIDSatahospitalinPhiladelphia.ShewasalsoservingasaclinicaltrialinvestigatorforPhase1and2MSDstudiesofanewclassofanti-HIVdrugsdesignedtoblocktheHIVproteaseenzymeandthuspreventHIVreplication."Theearlyresultswereexciting.Inashorttime,manypatientsrespondedtotheinvestigationaltreatment,"saysHedy.HerpositiveexperienceduringtheseandsubsequentclinicaltrialswaslargelywhyshejoinedMSDin1996."Iwantedtobemoreinvolvedindrugdevelopmentandclinicaltrialdesign,andMSDwasdoingsomegroundbreakingworkinHIV,"saysHedy,whonowservesasexecutivedirector,ClinicalResearch,InfectiousDiseases,atMSDResearchLaboratories.TheyearbeforeHedyarrived,anotherprominentHIVresearcherandthoughtleaderwaskeepingaclosewatchonMSD'swork.Bach-YenNguyen,nowretired-executivedirector,sectionhead,HCVandHIV,decidedtoleavetheNationalInstitutesofHealthtoworkonMSD'sHIVresearchdevelopmentteam.Bach-YenhadspentyearstreatingAIDSpatientsandworkinginHIVresearchandsawgreatpotentialinMSD'swork."WewerefacedwithanopportunitytohelppatientsinfectedwithHIV."ForBach-Yen,whoalsomadevitalcontributionstothedevelopmentofanotheroneofMSD'smedicinesforthetreatmentofHIV,thedrug'sapprovalcontinuestobehermostmemorablemomentatMSD."Weworkedlonghours.ThereweretimeswhenIcouldn'tattendschooleventswithmyson.WhenpeopleaskedhimwhereIwas,hewouldsay,'MomisbusyhelpingpeoplewithAIDS.'Hewasonly12,butheunderstoodtheimportanceofthework."Withinafewyears,theteamachievedadditionalsuccess:In2011,theFDAapprovedachewabletabletformofthisfirstagentinanewclassofanti-HIVagentsforchildren2yearsandolder,andin2013,approvedgranulesfororalsuspensionforinfants4weeksandolder."Ourpediatricsprogramhasbeenextremelysatisfyingasthereisatremendousneedfornewanti-HIVagentsthatcanbeusedacrosstheentirepediatricagerange,"saysHedy,wholeadstheIsentresspediatricdevelopmentprogram.“EventhoughDr.Alzheimercharacterizedthediseasein1906,itwasn’tuntilthelastfewdecadesthatthediseasebecamerecognizedasarealillnessseparatefromnormalagingandotherformsofdementia,”saidDarryleSchoepp,Ph.D.,vicepresidentandtherapeuticareahead,Neuroscience,MSD.“Nowpeoplearelivinglonger,andwecanseehowthediseaseworks,”saidDavidMichelson,M.D.,vicepresident,ClinicalNeuroscienceResearch,MSD.“Scienceisataplacewherenotonlydoweunderstandmoreaboutit,butweareexploringwaystodosomethingaboutit.”“Newtechnologiesareallowingtheidentificationofearlydiseasesignswhichwehopewillallowustointervenepromptlyinordertosloworhaltprogression.That’stheholygrail.Whatyouwanttodoistohavesomethingthatworksandtobeabletouseitbeforethediseaserobspeopleofwhotheyreallyare,”saidDr.Michelson.

  “EventhoughDr.Alzheimercharacterizedthediseasein1906,itwasn’tuntilthelastfewdecadesthatthediseasebecamerecognizedasarealillnessseparatefromnormalagingandotherformsofdementia,”saidDarryleSchoepp,Ph.D.,vicepresidentandtherapeuticareahead,Neuroscience,MSD.“Nowpeoplearelivinglonger,andwecanseehowthediseaseworks,”saidDavidMichelson,M.D.,vicepresident,ClinicalNeuroscienceResearch,MSD.“Scienceisataplacewherenotonlydoweunderstandmoreaboutit,butweareexploringwaystodosomethingaboutit.”“Newtechnologiesareallowingtheidentificationofearlydiseasesignswhichwehopewillallowustointervenepromptlyinordertosloworhaltprogression.That’stheholygrail.Whatyouwanttodoistohavesomethingthatworksandtobeabletouseitbeforethediseaserobspeopleofwhotheyreallyare,”saidDr.Michelson.Overthelast20years,MSD’svaccineoperationsinEuropehavebeenpartofajointventurebetweenthecompaniesSanofiandMSD,calledSanofiPasteurMSD(SPMSD).SanofiPasteurMSD—ownedona50/50basisbySanofiPasteurandMSD—wascreatedin1994todevelopandcommercializevaccinesoriginatingfrombothcompanies’pipelinestoimproveandpromotepublichealthin19Europeancountries.Aftercarefullyconsideringourindividualstrategicpriorities,alongsidetheeconomicandregulatoryenvironmentsforvaccineoperationsintheEuropeanUnion,bothcompaniesmutuallyagreedinMarchof2016thatitisinourbestintereststomanageourvaccineproductportfoliosindependently.SanofiPasteurandMSDbelievethatreintegratingtheirrespectivevaccineportfoliosintotheircompanies’operationswillbetterpositionthemtodrivegrowth,executemoreefficiently,optimizevaccinecoverageandbringnewvaccinestomarketmorequickly.Eachcompanywillnowbeabletodefineitsownvaccinesstrategytobenefitpublichealthandcreatevalueforpatients,healthcareprofessionalsandpayers.Throughouttheyear,SPMSDanditsshareholdershavebeenfocusedonasmoothandorderlytransitionwhileachievingtheirpublichealthcaregoalsandupholdingtheircommitmentstotheiremployees,customersandbusinesspartners.Followingthistransitionalperiod,bothcompanieshaveconfirmedthatDec.31,2016willbetheofficialclosingdateoftheendoftheirvaccinesjointventureSanofiPasteurMSD(SPMSD),followingclearancesrecentlygrantedbytheEuropeanCommission.AfyaSerengetiProjectFormorethan15years,haspartneredwiththe(Afyameans"health"inSwahili)intheSerengetiregionofTanzaniaineasternAfrica.Wehelpprovideaccesstopreventivecare,includingrabiesvaccinationsforlocaldogs.Todate,wehavedonatedtwomillionrabiesvaccinestosupportprogramsinIndia,Malawi,SriLanka,TanzaniaandUganda.Wealsoprovidetoolssuchasall-terrainvehiclesandtentstohelpmakesuretheprojectisabletoreachthemostremotecornersoftheregion.Rabiesinhumansanddomesticanimalshasnowbeenvirtuallyeliminatedfromthisareaandhumanhospitalizationsduetorabiddogbiteshavedecreased92percent.

  In1987,MSD’sthenCEODr.P.RoyVagelosannounced,inanunprecedentedactofglobalhealthcareleadership,thatMSDwoulddonateivermectin–asmuchasneededforaslongasneeded–withthegoaltohelpeliminateriverblindness.MSDrecognizedinordertoreachthisgoal,manyorganizationswithuniqueskillswouldneedtoworktogetherasateam.Asaresult,MSDcreatedtheMectizanDonationProgram(MDP).OperatingfromtheAtlanta-basedTaskForceforGlobalHealth,theMDPcoordinatesactivitiesbetweenMSD,WHO,theWorldBankandarangeofpublicandprivatestakeholders.In1998,MSDexpandeditscommitmentfromtheMectizanDonationProgramtoincludedonatingivermectinforanotherdisease,lymphaticfilariasis(LF),alsoknownaselephantiasis,inAfricancountriesandYemenwhereitco-existswithriverblindness.ForLF,ivermectinisadministeredwithalbendazole,adrugdonatedbyGSK.In1987,MSD’sthenCEODr.P.RoyVagelosannounced,inanunprecedentedactofglobalhealthcareleadership,thatMSDwoulddonateivermectin–asmuchasneededforaslongasneeded–withthegoaltohelpeliminateriverblindness.MSDrecognizedinordertoreachthisgoal,manyorganizationswithuniqueskillswouldneedtoworktogetherasateam.Asaresult,MSDcreatedtheMectizanDonationProgram(MDP).OperatingfromtheAtlanta-basedTaskForceforGlobalHealth,theMDPcoordinatesactivitiesbetweenMSD,WHO,theWorldBankandarangeofpublicandprivatestakeholders.In1998,MSDexpandeditscommitmentfromtheMectizanDonationProgramtoincludedonatingivermectinforanotherdisease,lymphaticfilariasis(LF),alsoknownaselephantiasis,inAfricancountriesandYemenwhereitco-existswithriverblindness.ForLF,ivermectinisadministeredwithalbendazole,adrugdonatedbyGSK.Ourdiscoveryscientists“strivetomaketheimpossiblepossible,”saysJoeMiletich.Andheshouldknow:AstheseniorvicepresidentofDiscoveryPreclinicalandEarlyDevelopment,heleadsateamofresearcherswhoarechargedwithmakingthings“possiblethatweren’tpossiblebefore.”Hecontinues:“Webelievedrugdiscoveryisfoundationalforustocontinuebringingcriticalmedicinestotheworld.”About14,500peopleareinvolvedinscientificresearchatMSD.OurRDcolleaguesarealltaskedwiththesamemission:tosolvethepuzzlesofhumandiseasebiologyandthentranslatethosefindingsintonewtherapiesforpatients.Theyaredriventopushtheboundariesofscienceandtothentransformtheirdiscoveriesintomeaningfulnewtherapeutics.

  Overthepast125years,we’veseentheworldchangethroughthepowerofmedicineandinvention.Whileeachpivotalmilestonehasbeenunique,onethingtheyhaveincommonisthatwehaven’tdoneitalone.AtMSD,wehavealwaysbelievedthatgreatmedicalbreakthroughsrelyonteamwork–fromwithinandoutsideofMSD–andourhistoryhasprovenit.Weareproudtohaveworkedinpartnershipwithcompanies,academics,governments,patientorganizations,healthcareprofessionals,nongovernmentalorganizations(NGOs),multilateralorganizationsandothersintheprivatesector--tohelpimprovelivesaroundtheworldandcontinuetosolvesomeoftheworld’smostseriousillnesses.Antibioticshaverevolutionizedmedicineinmanyrespects,andcountlessliveshavebeensaved;theirdiscoverywasaturningpointinhumanhistory.Foralmostacentury,bacteria-fightingdrugsknownasantibioticshavehelpedtomanagemanyoftheharmfulbacteriathatcanmakeussick.Butinrecentdecades,theyhavebecomelesseffectiveagainstsometypesofbacteria.Currently,certainbacteriaarenowunbeatablewithtoday’smedicines.Unfortunately,newdrug-resistant“superbugs”haveemerged,whicharestrainsofbacteriathatareresistanttoseveraltypesofantibiotics.Infact,theWorldHealthOrganizationhasclassifiedthisas“aseriousthreat[that]isnolongerapredictionforthefuture,itishappeningrightnowineveryregionoftheworldandhasthepotentialtoaffectanyone,ofanyage,inanycountry.”Intheearly1990s,HedyTepplerwastreatingAIDSpatientswithHIV/AIDSatahospitalinPhiladelphia.ShewasalsoservingasaclinicaltrialinvestigatorforPhase1and2MSDstudiesofanewclassofanti-HIVdrugsdesignedtoblocktheHIVproteaseenzymeandthuspreventHIVreplication."Theearlyresultswereexciting.Inashorttime,manypatientsrespondedtotheinvestigationaltreatment,"saysHedy.HerpositiveexperienceduringtheseandsubsequentclinicaltrialswaslargelywhyshejoinedMSDin1996."Iwantedtobemoreinvolvedindrugdevelopmentandclinicaltrialdesign,andMSDwasdoingsomegroundbreakingworkinHIV,"saysHedy,whonowservesasexecutivedirector,ClinicalResearch,InfectiousDiseases,atMSDResearchLaboratories.TheyearbeforeHedyarrived,anotherprominentHIVresearcherandthoughtleaderwaskeepingaclosewatchonMSD'swork.Bach-YenNguyen,nowretired-executivedirector,sectionhead,HCVandHIV,decidedtoleavetheNationalInstitutesofHealthtoworkonMSD'sHIVresearchdevelopmentteam.Bach-YenhadspentyearstreatingAIDSpatientsandworkinginHIVresearchandsawgreatpotentialinMSD'swork."WewerefacedwithanopportunitytohelppatientsinfectedwithHIV."ForBach-Yen,whoalsomadevitalcontributionstothedevelopmentofanotheroneofMSD'smedicinesforthetreatmentofHIV,thedrug'sapprovalcontinuestobehermostmemorablemomentatMSD."Weworkedlonghours.ThereweretimeswhenIcouldn'tattendschooleventswithmyson.WhenpeopleaskedhimwhereIwas,hewouldsay,'MomisbusyhelpingpeoplewithAIDS.'Hewasonly12,butheunderstoodtheimportanceofthework."Withinafewyears,theteamachievedadditionalsuccess:In2011,theFDAapprovedachewabletabletformofthisfirstagentinanewclassofanti-HIVagentsforchildren2yearsandolder,andin2013,approvedgranulesfororalsuspensionforinfants4weeksandolder."Ourpediatricsprogramhasbeenextremelysatisfyingasthereisatremendousneedfornewanti-HIVagentsthatcanbeusedacrosstheentirepediatricagerange,"saysHedy,wholeadstheIsentresspediatricdevelopmentprogram.

  Ourdiscoveryscientists“strivetomaketheimpossiblepossible,”saysJoeMiletich.Andheshouldknow:AstheseniorvicepresidentofDiscoveryPreclinicalandEarlyDevelopment,heleadsateamofresearcherswhoarechargedwithmakingthings“possiblethatweren’tpossiblebefore.”Hecontinues:“Webelievedrugdiscoveryisfoundationalforustocontinuebringingcriticalmedicinestotheworld.”About14,500peopleareinvolvedinscientificresearchatMSD.OurRDcolleaguesarealltaskedwiththesamemission:tosolvethepuzzlesofhumandiseasebiologyandthentranslatethosefindingsintonewtherapiesforpatients.Theyaredriventopushtheboundariesofscienceandtothentransformtheirdiscoveriesintomeaningfulnewtherapeutics.In2016,MSDcelebratedits125thanniversaryasaglobalhealthcareleader.Wecreatedthispageasacelebrationofouraccomplishmentsaswellastohighlightwhatwe'reexcitedaboutfortheyearstocome.Thisisanexcitingtimeforourcompanyandtheworld.Today,weareattheforefrontofinventingtoolsforthefightagainstsomeoftheworld’smosturgentglobalhealthchallenges.Thisincludesmorethan30differentcancers,hepatitisC,Alzheimer’sdisease,Ebola,antibiotic-resistantsuperbugs,cardio-metabolicdiseases,andmanyothers.Antibioticshaverevolutionizedmedicineinmanyrespects,andcountlessliveshavebeensaved;theirdiscoverywasaturningpointinhumanhistory.Foralmostacentury,bacteria-fightingdrugsknownasantibioticshavehelpedtomanagemanyoftheharmfulbacteriathatcanmakeussick.Butinrecentdecades,theyhavebecomelesseffectiveagainstsometypesofbacteria.Currently,certainbacteriaarenowunbeatablewithtoday’smedicines.Unfortunately,newdrug-resistant“superbugs”haveemerged,whicharestrainsofbacteriathatareresistanttoseveraltypesofantibiotics.Infact,theWorldHealthOrganizationhasclassifiedthisas“aseriousthreat[that]isnolongerapredictionforthefuture,itishappeningrightnowineveryregionoftheworldandhasthepotentialtoaffectanyone,ofanyage,inanycountry.”

  TheImpactofStigmatizationThesenorms,behaviors,andbeliefssurroundinghepatitisCinfectioncanleadtoalienationfromfamilyandfriends,aswellastodiscrimination(perceivedorreal)inhealthservicesandworkplaces.Indeed,manychronichepatitisCpatientsreportfeelingsofstigmatizationandsocialisolationfromtheirfriends,family,andcoworkers.WevetalkedtoHCVinfectedgrandmotherswhoseownchildrenwon’tallowthemtoplaywiththeirgrandchildrenbecausethey’reafraidofsomesortoftransmission,reportsMichaelNinburg,executivedirectoroftheHepatitisEducationProject,aSeattle-basedgroupfoundedin1993toprovideeducation,support,andadvocacyforthoselivingwithhepatitis.ArecentlydiagnosedpatientwhoworkswithMichael’sgroupechoedthissentiment.I'msuperoutgoing.ItalkabouteveryfeelingIhavetomyfriends,justaboutanybody,andmydiagnosiswassomethingIcouldnottalkabout,hesaid.IknewthatIhadtodosomethingaboutit,butIwasashamed.“EventhoughDr.Alzheimercharacterizedthediseasein1906,itwasn’tuntilthelastfewdecadesthatthediseasebecamerecognizedasarealillnessseparatefromnormalagingandotherformsofdementia,”saidDarryleSchoepp,Ph.D.,vicepresidentandtherapeuticareahead,Neuroscience,MSD.“Nowpeoplearelivinglonger,andwecanseehowthediseaseworks,”saidDavidMichelson,M.D.,vicepresident,ClinicalNeuroscienceResearch,MSD.“Scienceisataplacewherenotonlydoweunderstandmoreaboutit,butweareexploringwaystodosomethingaboutit.”“Newtechnologiesareallowingtheidentificationofearlydiseasesignswhichwehopewillallowustointervenepromptlyinordertosloworhaltprogression.That’stheholygrail.Whatyouwanttodoistohavesomethingthatworksandtobeabletouseitbeforethediseaserobspeopleofwhotheyreallyare,”saidDr.Michelson.Overthepast125years,we’veseentheworldchangethroughthepowerofmedicineandinvention.Whileeachpivotalmilestonehasbeenunique,onethingtheyhaveincommonisthatwehaven’tdoneitalone.AtMSD,wehavealwaysbelievedthatgreatmedicalbreakthroughsrelyonteamwork–fromwithinandoutsideofMSD–andourhistoryhasprovenit.Weareproudtohaveworkedinpartnershipwithcompanies,academics,governments,patientorganizations,healthcareprofessionals,nongovernmentalorganizations(NGOs),multilateralorganizationsandothersintheprivatesector--tohelpimprovelivesaroundtheworldandcontinuetosolvesomeoftheworld’smostseriousillnesses.

  TheMSDFellowshipforGlobalHealthisonewayMSDishelpinganswertheglobalhealthneedsoftheunderserved.MSDemployeeswhoparticipateintheprogramarecalledRichardT.ClarkFellows(RTCFellows)inhonorofretiredChairmanandCEORichardT.Clarkandhisphilosophyofpassion,purposeandcommitmenttocorporateresponsibility.Launchedin2012,theprogramoffersMSDemployeesopportunitiestosharetheirskillswithpeoplearoundtheworld.Asmanyas30Fellowsareselectedeachyear;theexpertiseoftheapplicantsismatchedtotheneedsofthepartnerorganizations.Duringthethree-monthassignments,theFellowsareembeddedwithinanon-profitorganizationinthefield.Intheearly1990s,HedyTepplerwastreatingAIDSpatientswithHIV/AIDSatahospitalinPhiladelphia.ShewasalsoservingasaclinicaltrialinvestigatorforPhase1and2MSDstudiesofanewclassofanti-HIVdrugsdesignedtoblocktheHIVproteaseenzymeandthuspreventHIVreplication."Theearlyresultswereexciting.Inashorttime,manypatientsrespondedtotheinvestigationaltreatment,"saysHedy.HerpositiveexperienceduringtheseandsubsequentclinicaltrialswaslargelywhyshejoinedMSDin1996."Iwantedtobemoreinvolvedindrugdevelopmentandclinicaltrialdesign,andMSDwasdoingsomegroundbreakingworkinHIV,"saysHedy,whonowservesasexecutivedirector,ClinicalResearch,InfectiousDiseases,atMSDResearchLaboratories.TheyearbeforeHedyarrived,anotherprominentHIVresearcherandthoughtleaderwaskeepingaclosewatchonMSD'swork.Bach-YenNguyen,nowretired-executivedirector,sectionhead,HCVandHIV,decidedtoleavetheNationalInstitutesofHealthtoworkonMSD'sHIVresearchdevelopmentteam.Bach-YenhadspentyearstreatingAIDSpatientsandworkinginHIVresearchandsawgreatpotentialinMSD'swork."WewerefacedwithanopportunitytohelppatientsinfectedwithHIV."ForBach-Yen,whoalsomadevitalcontributionstothedevelopmentofanotheroneofMSD'smedicinesforthetreatmentofHIV,thedrug'sapprovalcontinuestobehermostmemorablemomentatMSD."Weworkedlonghours.ThereweretimeswhenIcouldn'tattendschooleventswithmyson.WhenpeopleaskedhimwhereIwas,hewouldsay,'MomisbusyhelpingpeoplewithAIDS.'Hewasonly12,butheunderstoodtheimportanceofthework."Withinafewyears,theteamachievedadditionalsuccess:In2011,theFDAapprovedachewabletabletformofthisfirstagentinanewclassofanti-HIVagentsforchildren2yearsandolder,andin2013,approvedgranulesfororalsuspensionforinfants4weeksandolder."Ourpediatricsprogramhasbeenextremelysatisfyingasthereisatremendousneedfornewanti-HIVagentsthatcanbeusedacrosstheentirepediatricagerange,"saysHedy,wholeadstheIsentresspediatricdevelopmentprogram.In2016,MSDcelebratedits125thanniversaryasaglobalhealthcareleader.Wecreatedthispageasacelebrationofouraccomplishmentsaswellastohighlightwhatwe'reexcitedaboutfortheyearstocome.Thisisanexcitingtimeforourcompanyandtheworld.Today,weareattheforefrontofinventingtoolsforthefightagainstsomeoftheworld’smosturgentglobalhealthchallenges.Thisincludesmorethan30differentcancers,hepatitisC,Alzheimer’sdisease,Ebola,antibiotic-resistantsuperbugs,cardio-metabolicdiseases,andmanyothers.

  ELIAV:HCV[hepatitisCvirus]infectionisablood-bornedisease.Peoplebecomeinfectedwhenexposedtocontaminatedbloodproductsorcontaminatedsyringesorinjectionequipment.TheincidenceofHCVinfection(thenknownasnon-A/non-Bhepatitis)priorto1965waslow;however,therateincreasedsteadilyintothe1980s.In1988,HCVwasidentifiedandbloodsupplyscreeningforHCVbecameavailablein1992.Peoplegotinfectedandusuallydidn'tknowitbecausetheacuteinfectionistypicallyasymptomatic.Afterprolongedinfection,20to25years,orso,peoplewerepresentingwithadvancedliverdamage,whichcanleadtocirrhosisandeventuallyevenliverfailureorlivercancer.Ahugecohortofbabyboomersgotinfected,didn'tknowit,aregraduallygettingdiagnosedandfindingtheirdiseaseissoadvancedthattheyareapproachingacrisispoint.Theclockistickingonthisproblem.Intheearly1990s,HedyTepplerwastreatingAIDSpatientswithHIV/AIDSatahospitalinPhiladelphia.ShewasalsoservingasaclinicaltrialinvestigatorforPhase1and2MSDstudiesofanewclassofanti-HIVdrugsdesignedtoblocktheHIVproteaseenzymeandthuspreventHIVreplication."Theearlyresultswereexciting.Inashorttime,manypatientsrespondedtotheinvestigationaltreatment,"saysHedy.HerpositiveexperienceduringtheseandsubsequentclinicaltrialswaslargelywhyshejoinedMSDin1996."Iwantedtobemoreinvolvedindrugdevelopmentandclinicaltrialdesign,andMSDwasdoingsomegroundbreakingworkinHIV,"saysHedy,whonowservesasexecutivedirector,ClinicalResearch,InfectiousDiseases,atMSDResearchLaboratories.TheyearbeforeHedyarrived,anotherprominentHIVresearcherandthoughtleaderwaskeepingaclosewatchonMSD'swork.Bach-YenNguyen,nowretired-executivedirector,sectionhead,HCVandHIV,decidedtoleavetheNationalInstitutesofHealthtoworkonMSD'sHIVresearchdevelopmentteam.Bach-YenhadspentyearstreatingAIDSpatientsandworkinginHIVresearchandsawgreatpotentialinMSD'swork."WewerefacedwithanopportunitytohelppatientsinfectedwithHIV."ForBach-Yen,whoalsomadevitalcontributionstothedevelopmentofanotheroneofMSD'smedicinesforthetreatmentofHIV,thedrug'sapprovalcontinuestobehermostmemorablemomentatMSD."Weworkedlonghours.ThereweretimeswhenIcouldn'tattendschooleventswithmyson.WhenpeopleaskedhimwhereIwas,hewouldsay,'MomisbusyhelpingpeoplewithAIDS.'Hewasonly12,butheunderstoodtheimportanceofthework."Withinafewyears,theteamachievedadditionalsuccess:In2011,theFDAapprovedachewabletabletformofthisfirstagentinanewclassofanti-HIVagentsforchildren2yearsandolder,andin2013,approvedgranulesfororalsuspensionforinfants4weeksandolder."Ourpediatricsprogramhasbeenextremelysatisfyingasthereisatremendousneedfornewanti-HIVagentsthatcanbeusedacrosstheentirepediatricagerange,"saysHedy,wholeadstheIsentresspediatricdevelopmentprogram.Ourdiscoveryscientists“strivetomaketheimpossiblepossible,”saysJoeMiletich.Andheshouldknow:AstheseniorvicepresidentofDiscoveryPreclinicalandEarlyDevelopment,heleadsateamofresearcherswhoarechargedwithmakingthings“possiblethatweren’tpossiblebefore.”Hecontinues:“Webelievedrugdiscoveryisfoundationalforustocontinuebringingcriticalmedicinestotheworld.”About14,500peopleareinvolvedinscientificresearchatMSD.OurRDcolleaguesarealltaskedwiththesamemission:tosolvethepuzzlesofhumandiseasebiologyandthentranslatethosefindingsintonewtherapiesforpatients.Theyaredriventopushtheboundariesofscienceandtothentransformtheirdiscoveriesintomeaningfulnewtherapeutics.

  AfyaSerengetiProjectFormorethan15years,haspartneredwiththe(Afyameans"health"inSwahili)intheSerengetiregionofTanzaniaineasternAfrica.Wehelpprovideaccesstopreventivecare,includingrabiesvaccinationsforlocaldogs.Todate,wehavedonatedtwomillionrabiesvaccinestosupportprogramsinIndia,Malawi,SriLanka,TanzaniaandUganda.Wealsoprovidetoolssuchasall-terrainvehiclesandtentstohelpmakesuretheprojectisabletoreachthemostremotecornersoftheregion.Rabiesinhumansanddomesticanimalshasnowbeenvirtuallyeliminatedfromthisareaandhumanhospitalizationsduetorabiddogbiteshavedecreased92percent.Intheearly1990s,HedyTepplerwastreatingAIDSpatientswithHIV/AIDSatahospitalinPhiladelphia.ShewasalsoservingasaclinicaltrialinvestigatorforPhase1and2MSDstudiesofanewclassofanti-HIVdrugsdesignedtoblocktheHIVproteaseenzymeandthuspreventHIVreplication."Theearlyresultswereexciting.Inashorttime,manypatientsrespondedtotheinvestigationaltreatment,"saysHedy.HerpositiveexperienceduringtheseandsubsequentclinicaltrialswaslargelywhyshejoinedMSDin1996."Iwantedtobemoreinvolvedindrugdevelopmentandclinicaltrialdesign,andMSDwasdoingsomegroundbreakingworkinHIV,"saysHedy,whonowservesasexecutivedirector,ClinicalResearch,InfectiousDiseases,atMSDResearchLaboratories.TheyearbeforeHedyarrived,anotherprominentHIVresearcherandthoughtleaderwaskeepingaclosewatchonMSD'swork.Bach-YenNguyen,nowretired-executivedirector,sectionhead,HCVandHIV,decidedtoleavetheNationalInstitutesofHealthtoworkonMSD'sHIVresearchdevelopmentteam.Bach-YenhadspentyearstreatingAIDSpatientsandworkinginHIVresearchandsawgreatpotentialinMSD'swork."WewerefacedwithanopportunitytohelppatientsinfectedwithHIV."ForBach-Yen,whoalsomadevitalcontributionstothedevelopmentofanotheroneofMSD'smedicinesforthetreatmentofHIV,thedrug'sapprovalcontinuestobehermostmemorablemomentatMSD."Weworkedlonghours.ThereweretimeswhenIcouldn'tattendschooleventswithmyson.WhenpeopleaskedhimwhereIwas,hewouldsay,'MomisbusyhelpingpeoplewithAIDS.'Hewasonly12,butheunderstoodtheimportanceofthework."Withinafewyears,theteamachievedadditionalsuccess:In2011,theFDAapprovedachewabletabletformofthisfirstagentinanewclassofanti-HIVagentsforchildren2yearsandolder,andin2013,approvedgranulesfororalsuspensionforinfants4weeksandolder."Ourpediatricsprogramhasbeenextremelysatisfyingasthereisatremendousneedfornewanti-HIVagentsthatcanbeusedacrosstheentirepediatricagerange,"saysHedy,wholeadstheIsentresspediatricdevelopmentprogram.“EventhoughDr.Alzheimercharacterizedthediseasein1906,itwasn’tuntilthelastfewdecadesthatthediseasebecamerecognizedasarealillnessseparatefromnormalagingandotherformsofdementia,”saidDarryleSchoepp,Ph.D.,vicepresidentandtherapeuticareahead,Neuroscience,MSD.“Nowpeoplearelivinglonger,andwecanseehowthediseaseworks,”saidDavidMichelson,M.D.,vicepresident,ClinicalNeuroscienceResearch,MSD.“Scienceisataplacewherenotonlydoweunderstandmoreaboutit,butweareexploringwaystodosomethingaboutit.”“Newtechnologiesareallowingtheidentificationofearlydiseasesignswhichwehopewillallowustointervenepromptlyinordertosloworhaltprogression.That’stheholygrail.Whatyouwanttodoistohavesomethingthatworksandtobeabletouseitbeforethediseaserobspeopleofwhotheyreallyare,”saidDr.Michelson.

  “EventhoughDr.Alzheimercharacterizedthediseasein1906,itwasn’tuntilthelastfewdecadesthatthediseasebecamerecognizedasarealillnessseparatefromnormalagingandotherformsofdementia,”saidDarryleSchoepp,Ph.D.,vicepresidentandtherapeuticareahead,Neuroscience,MSD.“Nowpeoplearelivinglonger,andwecanseehowthediseaseworks,”saidDavidMichelson,M.D.,vicepresident,ClinicalNeuroscienceResearch,MSD.“Scienceisataplacewherenotonlydoweunderstandmoreaboutit,butweareexploringwaystodosomethingaboutit.”“Newtechnologiesareallowingtheidentificationofearlydiseasesignswhichwehopewillallowustointervenepromptlyinordertosloworhaltprogression.That’stheholygrail.Whatyouwanttodoistohavesomethingthatworksandtobeabletouseitbeforethediseaserobspeopleofwhotheyreallyare,”saidDr.Michelson.In2016,MSDcelebratedits125thanniversaryasaglobalhealthcareleader.Wecreatedthispageasacelebrationofouraccomplishmentsaswellastohighlightwhatwe'reexcitedaboutfortheyearstocome.Thisisanexcitingtimeforourcompanyandtheworld.Today,weareattheforefrontofinventingtoolsforthefightagainstsomeoftheworld’smosturgentglobalhealthchallenges.Thisincludesmorethan30differentcancers,hepatitisC,Alzheimer’sdisease,Ebola,antibiotic-resistantsuperbugs,cardio-metabolicdiseases,andmanyothers.Antibioticshaverevolutionizedmedicineinmanyrespects,andcountlessliveshavebeensaved;theirdiscoverywasaturningpointinhumanhistory.Foralmostacentury,bacteria-fightingdrugsknownasantibioticshavehelpedtomanagemanyoftheharmfulbacteriathatcanmakeussick.Butinrecentdecades,theyhavebecomelesseffectiveagainstsometypesofbacteria.Currently,certainbacteriaarenowunbeatablewithtoday’smedicines.Unfortunately,newdrug-resistant“superbugs”haveemerged,whicharestrainsofbacteriathatareresistanttoseveraltypesofantibiotics.Infact,theWorldHealthOrganizationhasclassifiedthisas“aseriousthreat[that]isnolongerapredictionforthefuture,itishappeningrightnowineveryregionoftheworldandhasthepotentialtoaffectanyone,ofanyage,inanycountry.”

  Ourdiscoveryscientists“strivetomaketheimpossiblepossible,”saysJoeMiletich.Andheshouldknow:AstheseniorvicepresidentofDiscoveryPreclinicalandEarlyDevelopment,heleadsateamofresearcherswhoarechargedwithmakingthings“possiblethatweren’tpossiblebefore.”Hecontinues:“Webelievedrugdiscoveryisfoundationalforustocontinuebringingcriticalmedicinestotheworld.”About14,500peopleareinvolvedinscientificresearchatMSD.OurRDcolleaguesarealltaskedwiththesamemission:tosolvethepuzzlesofhumandiseasebiologyandthentranslatethosefindingsintonewtherapiesforpatients.Theyaredriventopushtheboundariesofscienceandtothentransformtheirdiscoveriesintomeaningfulnewtherapeutics.Intheearly1990s,HedyTepplerwastreatingAIDSpatientswithHIV/AIDSatahospitalinPhiladelphia.ShewasalsoservingasaclinicaltrialinvestigatorforPhase1and2MSDstudiesofanewclassofanti-HIVdrugsdesignedtoblocktheHIVproteaseenzymeandthuspreventHIVreplication."Theearlyresultswereexciting.Inashorttime,manypatientsrespondedtotheinvestigationaltreatment,"saysHedy.HerpositiveexperienceduringtheseandsubsequentclinicaltrialswaslargelywhyshejoinedMSDin1996."Iwantedtobemoreinvolvedindrugdevelopmentandclinicaltrialdesign,andMSDwasdoingsomegroundbreakingworkinHIV,"saysHedy,whonowservesasexecutivedirector,ClinicalResearch,InfectiousDiseases,atMSDResearchLaboratories.TheyearbeforeHedyarrived,anotherprominentHIVresearcherandthoughtleaderwaskeepingaclosewatchonMSD'swork.Bach-YenNguyen,nowretired-executivedirector,sectionhead,HCVandHIV,decidedtoleavetheNationalInstitutesofHealthtoworkonMSD'sHIVresearchdevelopmentteam.Bach-YenhadspentyearstreatingAIDSpatientsandworkinginHIVresearchandsawgreatpotentialinMSD'swork."WewerefacedwithanopportunitytohelppatientsinfectedwithHIV."ForBach-Yen,whoalsomadevitalcontributionstothedevelopmentofanotheroneofMSD'smedicinesforthetreatmentofHIV,thedrug'sapprovalcontinuestobehermostmemorablemomentatMSD."Weworkedlonghours.ThereweretimeswhenIcouldn'tattendschooleventswithmyson.WhenpeopleaskedhimwhereIwas,hewouldsay,'MomisbusyhelpingpeoplewithAIDS.'Hewasonly12,butheunderstoodtheimportanceofthework."Withinafewyears,theteamachievedadditionalsuccess:In2011,theFDAapprovedachewabletabletformofthisfirstagentinanewclassofanti-HIVagentsforchildren2yearsandolder,andin2013,approvedgranulesfororalsuspensionforinfants4weeksandolder."Ourpediatricsprogramhasbeenextremelysatisfyingasthereisatremendousneedfornewanti-HIVagentsthatcanbeusedacrosstheentirepediatricagerange,"saysHedy,wholeadstheIsentresspediatricdevelopmentprogram.“EventhoughDr.Alzheimercharacterizedthediseasein1906,itwasn’tuntilthelastfewdecadesthatthediseasebecamerecognizedasarealillnessseparatefromnormalagingandotherformsofdementia,”saidDarryleSchoepp,Ph.D.,vicepresidentandtherapeuticareahead,Neuroscience,MSD.“Nowpeoplearelivinglonger,andwecanseehowthediseaseworks,”saidDavidMichelson,M.D.,vicepresident,ClinicalNeuroscienceResearch,MSD.“Scienceisataplacewherenotonlydoweunderstandmoreaboutit,butweareexploringwaystodosomethingaboutit.”“Newtechnologiesareallowingtheidentificationofearlydiseasesignswhichwehopewillallowustointervenepromptlyinordertosloworhaltprogression.That’stheholygrail.Whatyouwanttodoistohavesomethingthatworksandtobeabletouseitbeforethediseaserobspeopleofwhotheyreallyare,”saidDr.Michelson.

  Ourdiscoveryscientists“strivetomaketheimpossiblepossible,”saysJoeMiletich.Andheshouldknow:AstheseniorvicepresidentofDiscoveryPreclinicalandEarlyDevelopment,heleadsateamofresearcherswhoarechargedwithmakingthings“possiblethatweren’tpossiblebefore.”Hecontinues:“Webelievedrugdiscoveryisfoundationalforustocontinuebringingcriticalmedicinestotheworld.”About14,500peopleareinvolvedinscientificresearchatMSD.OurRDcolleaguesarealltaskedwiththesamemission:tosolvethepuzzlesofhumandiseasebiologyandthentranslatethosefindingsintonewtherapiesforpatients.Theyaredriventopushtheboundariesofscienceandtothentransformtheirdiscoveriesintomeaningfulnewtherapeutics.In2016,MSDcelebratedits125thanniversaryasaglobalhealthcareleader.Wecreatedthispageasacelebrationofouraccomplishmentsaswellastohighlightwhatwe'reexcitedaboutfortheyearstocome.Thisisanexcitingtimeforourcompanyandtheworld.Today,weareattheforefrontofinventingtoolsforthefightagainstsomeoftheworld’smosturgentglobalhealthchallenges.Thisincludesmorethan30differentcancers,hepatitisC,Alzheimer’sdisease,Ebola,antibiotic-resistantsuperbugs,cardio-metabolicdiseases,andmanyothers.Antibioticshaverevolutionizedmedicineinmanyrespects,andcountlessliveshavebeensaved;theirdiscoverywasaturningpointinhumanhistory.Foralmostacentury,bacteria-fightingdrugsknownasantibioticshavehelpedtomanagemanyoftheharmfulbacteriathatcanmakeussick.Butinrecentdecades,theyhavebecomelesseffectiveagainstsometypesofbacteria.Currently,certainbacteriaarenowunbeatablewithtoday’smedicines.Unfortunately,newdrug-resistant“superbugs”haveemerged,whicharestrainsofbacteriathatareresistanttoseveraltypesofantibiotics.Infact,theWorldHealthOrganizationhasclassifiedthisas“aseriousthreat[that]isnolongerapredictionforthefuture,itishappeningrightnowineveryregionoftheworldandhasthepotentialtoaffectanyone,ofanyage,inanycountry.”

  HbA1c,ameasureoftheaveragelevelofbloodsugaroverthepasttwotothreemonths,helpsyouandyourdoctorseehowwellyourdiabetestreatmentplanisworking.TherecommendedHbA1c,goalformanyadultswithtype2diabetesislessthan7%;however,thismayvarydependingontheindividual.Highbloodsugarlevelsovertimecanputpeoplewithdiabetesatriskofmanyserioushealthproblems,suchasheartdisease,stroke,kidneydisease,blindnessandnerveproblems.That’swhyitisimportantforpeoplelivingwithdiabetestoworkwiththeirdoctortosetindividualizedgoalsanddevelopapersonalizeddiabetesmanagementplantomanagetheABCsofdiabetes:AforHbA1c,BforbloodpressureandCforcholesterol.Ourdiscoveryscientists“strivetomaketheimpossiblepossible,”saysJoeMiletich.Andheshouldknow:AstheseniorvicepresidentofDiscoveryPreclinicalandEarlyDevelopment,heleadsateamofresearcherswhoarechargedwithmakingthings“possiblethatweren’tpossiblebefore.”Hecontinues:“Webelievedrugdiscoveryisfoundationalforustocontinuebringingcriticalmedicinestotheworld.”About14,500peopleareinvolvedinscientificresearchatMSD.OurRDcolleaguesarealltaskedwiththesamemission:tosolvethepuzzlesofhumandiseasebiologyandthentranslatethosefindingsintonewtherapiesforpatients.Theyaredriventopushtheboundariesofscienceandtothentransformtheirdiscoveriesintomeaningfulnewtherapeutics.AfyaSerengetiProjectFormorethan15years,haspartneredwiththe(Afyameans"health"inSwahili)intheSerengetiregionofTanzaniaineasternAfrica.Wehelpprovideaccesstopreventivecare,includingrabiesvaccinationsforlocaldogs.Todate,wehavedonatedtwomillionrabiesvaccinestosupportprogramsinIndia,Malawi,SriLanka,TanzaniaandUganda.Wealsoprovidetoolssuchasall-terrainvehiclesandtentstohelpmakesuretheprojectisabletoreachthemostremotecornersoftheregion.Rabiesinhumansanddomesticanimalshasnowbeenvirtuallyeliminatedfromthisareaandhumanhospitalizationsduetorabiddogbiteshavedecreased92percent.

  Overthepast125years,we’veseentheworldchangethroughthepowerofmedicineandinvention.Whileeachpivotalmilestonehasbeenunique,onethingtheyhaveincommonisthatwehaven’tdoneitalone.AtMSD,wehavealwaysbelievedthatgreatmedicalbreakthroughsrelyonteamwork–fromwithinandoutsideofMSD–andourhistoryhasprovenit.Weareproudtohaveworkedinpartnershipwithcompanies,academics,governments,patientorganizations,healthcareprofessionals,nongovernmentalorganizations(NGOs),multilateralorganizationsandothersintheprivatesector--tohelpimprovelivesaroundtheworldandcontinuetosolvesomeoftheworld’smostseriousillnesses.TheImpactofStigmatizationThesenorms,behaviors,andbeliefssurroundinghepatitisCinfectioncanleadtoalienationfromfamilyandfriends,aswellastodiscrimination(perceivedorreal)inhealthservicesandworkplaces.Indeed,manychronichepatitisCpatientsreportfeelingsofstigmatizationandsocialisolationfromtheirfriends,family,andcoworkers.WevetalkedtoHCVinfectedgrandmotherswhoseownchildrenwon’tallowthemtoplaywiththeirgrandchildrenbecausethey’reafraidofsomesortoftransmission,reportsMichaelNinburg,executivedirectoroftheHepatitisEducationProject,aSeattle-basedgroupfoundedin1993toprovideeducation,support,andadvocacyforthoselivingwithhepatitis.ArecentlydiagnosedpatientwhoworkswithMichael’sgroupechoedthissentiment.I'msuperoutgoing.ItalkabouteveryfeelingIhavetomyfriends,justaboutanybody,andmydiagnosiswassomethingIcouldnottalkabout,hesaid.IknewthatIhadtodosomethingaboutit,butIwasashamed.AfyaSerengetiProjectFormorethan15years,haspartneredwiththe(Afyameans"health"inSwahili)intheSerengetiregionofTanzaniaineasternAfrica.Wehelpprovideaccesstopreventivecare,includingrabiesvaccinationsforlocaldogs.Todate,wehavedonatedtwomillionrabiesvaccinestosupportprogramsinIndia,Malawi,SriLanka,TanzaniaandUganda.Wealsoprovidetoolssuchasall-terrainvehiclesandtentstohelpmakesuretheprojectisabletoreachthemostremotecornersoftheregion.Rabiesinhumansanddomesticanimalshasnowbeenvirtuallyeliminatedfromthisareaandhumanhospitalizationsduetorabiddogbiteshavedecreased92percent.

  Overthelast20years,MSD’svaccineoperationsinEuropehavebeenpartofajointventurebetweenthecompaniesSanofiandMSD,calledSanofiPasteurMSD(SPMSD).SanofiPasteurMSD—ownedona50/50basisbySanofiPasteurandMSD—wascreatedin1994todevelopandcommercializevaccinesoriginatingfrombothcompanies’pipelinestoimproveandpromotepublichealthin19Europeancountries.Aftercarefullyconsideringourindividualstrategicpriorities,alongsidetheeconomicandregulatoryenvironmentsforvaccineoperationsintheEuropeanUnion,bothcompaniesmutuallyagreedinMarchof2016thatitisinourbestintereststomanageourvaccineproductportfoliosindependently.SanofiPasteurandMSDbelievethatreintegratingtheirrespectivevaccineportfoliosintotheircompanies’operationswillbetterpositionthemtodrivegrowth,executemoreefficiently,optimizevaccinecoverageandbringnewvaccinestomarketmorequickly.Eachcompanywillnowbeabletodefineitsownvaccinesstrategytobenefitpublichealthandcreatevalueforpatients,healthcareprofessionalsandpayers.Throughouttheyear,SPMSDanditsshareholdershavebeenfocusedonasmoothandorderlytransitionwhileachievingtheirpublichealthcaregoalsandupholdingtheircommitmentstotheiremployees,customersandbusinesspartners.Followingthistransitionalperiod,bothcompanieshaveconfirmedthatDec.31,2016willbetheofficialclosingdateoftheendoftheirvaccinesjointventureSanofiPasteurMSD(SPMSD),followingclearancesrecentlygrantedbytheEuropeanCommission.Antibioticshaverevolutionizedmedicineinmanyrespects,andcountlessliveshavebeensaved;theirdiscoverywasaturningpointinhumanhistory.Foralmostacentury,bacteria-fightingdrugsknownasantibioticshavehelpedtomanagemanyoftheharmfulbacteriathatcanmakeussick.Butinrecentdecades,theyhavebecomelesseffectiveagainstsometypesofbacteria.Currently,certainbacteriaarenowunbeatablewithtoday’smedicines.Unfortunately,newdrug-resistant“superbugs”haveemerged,whicharestrainsofbacteriathatareresistanttoseveraltypesofantibiotics.Infact,theWorldHealthOrganizationhasclassifiedthisas“aseriousthreat[that]isnolongerapredictionforthefuture,itishappeningrightnowineveryregionoftheworldandhasthepotentialtoaffectanyone,ofanyage,inanycountry.”Overthelast20years,MSD’svaccineoperationsinEuropehavebeenpartofajointventurebetweenthecompaniesSanofiandMSD,calledSanofiPasteurMSD(SPMSD).SanofiPasteurMSD—ownedona50/50basisbySanofiPasteurandMSD—wascreatedin1994todevelopandcommercializevaccinesoriginatingfrombothcompanies’pipelinestoimproveandpromotepublichealthin19Europeancountries.Aftercarefullyconsideringourindividualstrategicpriorities,alongsidetheeconomicandregulatoryenvironmentsforvaccineoperationsintheEuropeanUnion,bothcompaniesmutuallyagreedinMarchof2016thatitisinourbestintereststomanageourvaccineproductportfoliosindependently.SanofiPasteurandMSDbelievethatreintegratingtheirrespectivevaccineportfoliosintotheircompanies’operationswillbetterpositionthemtodrivegrowth,executemoreefficiently,optimizevaccinecoverageandbringnewvaccinestomarketmorequickly.Eachcompanywillnowbeabletodefineitsownvaccinesstrategytobenefitpublichealthandcreatevalueforpatients,healthcareprofessionalsandpayers.Throughouttheyear,SPMSDanditsshareholdershavebeenfocusedonasmoothandorderlytransitionwhileachievingtheirpublichealthcaregoalsandupholdingtheircommitmentstotheiremployees,customersandbusinesspartners.Followingthistransitionalperiod,bothcompanieshaveconfirmedthatDec.31,2016willbetheofficialclosingdateoftheendoftheirvaccinesjointventureSanofiPasteurMSD(SPMSD),followingclearancesrecentlygrantedbytheEuropeanCommission.

  Overthelast20years,MSD’svaccineoperationsinEuropehavebeenpartofajointventurebetweenthecompaniesSanofiandMSD,calledSanofiPasteurMSD(SPMSD).SanofiPasteurMSD—ownedona50/50basisbySanofiPasteurandMSD—wascreatedin1994todevelopandcommercializevaccinesoriginatingfrombothcompanies’pipelinestoimproveandpromotepublichealthin19Europeancountries.Aftercarefullyconsideringourindividualstrategicpriorities,alongsidetheeconomicandregulatoryenvironmentsforvaccineoperationsintheEuropeanUnion,bothcompaniesmutuallyagreedinMarchof2016thatitisinourbestintereststomanageourvaccineproductportfoliosindependently.SanofiPasteurandMSDbelievethatreintegratingtheirrespectivevaccineportfoliosintotheircompanies’operationswillbetterpositionthemtodrivegrowth,executemoreefficiently,optimizevaccinecoverageandbringnewvaccinestomarketmorequickly.Eachcompanywillnowbeabletodefineitsownvaccinesstrategytobenefitpublichealthandcreatevalueforpatients,healthcareprofessionalsandpayers.Throughouttheyear,SPMSDanditsshareholdershavebeenfocusedonasmoothandorderlytransitionwhileachievingtheirpublichealthcaregoalsandupholdingtheircommitmentstotheiremployees,customersandbusinesspartners.Followingthistransitionalperiod,bothcompanieshaveconfirmedthatDec.31,2016willbetheofficialclosingdateoftheendoftheirvaccinesjointventureSanofiPasteurMSD(SPMSD),followingclearancesrecentlygrantedbytheEuropeanCommission.TheMSDFellowshipforGlobalHealthisonewayMSDishelpinganswertheglobalhealthneedsoftheunderserved.MSDemployeeswhoparticipateintheprogramarecalledRichardT.ClarkFellows(RTCFellows)inhonorofretiredChairmanandCEORichardT.Clarkandhisphilosophyofpassion,purposeandcommitmenttocorporateresponsibility.Launchedin2012,theprogramoffersMSDemployeesopportunitiestosharetheirskillswithpeoplearoundtheworld.Asmanyas30Fellowsareselectedeachyear;theexpertiseoftheapplicantsismatchedtotheneedsofthepartnerorganizations.Duringthethree-monthassignments,theFellowsareembeddedwithinanon-profitorganizationinthefield.TheMSDFellowshipforGlobalHealthisonewayMSDishelpinganswertheglobalhealthneedsoftheunderserved.MSDemployeeswhoparticipateintheprogramarecalledRichardT.ClarkFellows(RTCFellows)inhonorofretiredChairmanandCEORichardT.Clarkandhisphilosophyofpassion,purposeandcommitmenttocorporateresponsibility.Launchedin2012,theprogramoffersMSDemployeesopportunitiestosharetheirskillswithpeoplearoundtheworld.Asmanyas30Fellowsareselectedeachyear;theexpertiseoftheapplicantsismatchedtotheneedsofthepartnerorganizations.Duringthethree-monthassignments,theFellowsareembeddedwithinanon-profitorganizationinthefield.

  Ourdiscoveryscientists“strivetomaketheimpossiblepossible,”saysJoeMiletich.Andheshouldknow:AstheseniorvicepresidentofDiscoveryPreclinicalandEarlyDevelopment,heleadsateamofresearcherswhoarechargedwithmakingthings“possiblethatweren’tpossiblebefore.”Hecontinues:“Webelievedrugdiscoveryisfoundationalforustocontinuebringingcriticalmedicinestotheworld.”About14,500peopleareinvolvedinscientificresearchatMSD.OurRDcolleaguesarealltaskedwiththesamemission:tosolvethepuzzlesofhumandiseasebiologyandthentranslatethosefindingsintonewtherapiesforpatients.Theyaredriventopushtheboundariesofscienceandtothentransformtheirdiscoveriesintomeaningfulnewtherapeutics.TheMSDFellowshipforGlobalHealthisonewayMSDishelpinganswertheglobalhealthneedsoftheunderserved.MSDemployeeswhoparticipateintheprogramarecalledRichardT.ClarkFellows(RTCFellows)inhonorofretiredChairmanandCEORichardT.Clarkandhisphilosophyofpassion,purposeandcommitmenttocorporateresponsibility.Launchedin2012,theprogramoffersMSDemployeesopportunitiestosharetheirskillswithpeoplearoundtheworld.Asmanyas30Fellowsareselectedeachyear;theexpertiseoftheapplicantsismatchedtotheneedsofthepartnerorganizations.Duringthethree-monthassignments,theFellowsareembeddedwithinanon-profitorganizationinthefield.In1987,MSD’sthenCEODr.P.RoyVagelosannounced,inanunprecedentedactofglobalhealthcareleadership,thatMSDwoulddonateivermectin–asmuchasneededforaslongasneeded–withthegoaltohelpeliminateriverblindness.MSDrecognizedinordertoreachthisgoal,manyorganizationswithuniqueskillswouldneedtoworktogetherasateam.Asaresult,MSDcreatedtheMectizanDonationProgram(MDP).OperatingfromtheAtlanta-basedTaskForceforGlobalHealth,theMDPcoordinatesactivitiesbetweenMSD,WHO,theWorldBankandarangeofpublicandprivatestakeholders.In1998,MSDexpandeditscommitmentfromtheMectizanDonationProgramtoincludedonatingivermectinforanotherdisease,lymphaticfilariasis(LF),alsoknownaselephantiasis,inAfricancountriesandYemenwhereitco-existswithriverblindness.ForLF,ivermectinisadministeredwithalbendazole,adrugdonatedbyGSK.

  Overthelast20years,MSD’svaccineoperationsinEuropehavebeenpartofajointventurebetweenthecompaniesSanofiandMSD,calledSanofiPasteurMSD(SPMSD).SanofiPasteurMSD—ownedona50/50basisbySanofiPasteurandMSD—wascreatedin1994todevelopandcommercializevaccinesoriginatingfrombothcompanies’pipelinestoimproveandpromotepublichealthin19Europeancountries.Aftercarefullyconsideringourindividualstrategicpriorities,alongsidetheeconomicandregulatoryenvironmentsforvaccineoperationsintheEuropeanUnion,bothcompaniesmutuallyagreedinMarchof2016thatitisinourbestintereststomanageourvaccineproductportfoliosindependently.SanofiPasteurandMSDbelievethatreintegratingtheirrespectivevaccineportfoliosintotheircompanies’operationswillbetterpositionthemtodrivegrowth,executemoreefficiently,optimizevaccinecoverageandbringnewvaccinestomarketmorequickly.Eachcompanywillnowbeabletodefineitsownvaccinesstrategytobenefitpublichealthandcreatevalueforpatients,healthcareprofessionalsandpayers.Throughouttheyear,SPMSDanditsshareholdershavebeenfocusedonasmoothandorderlytransitionwhileachievingtheirpublichealthcaregoalsandupholdingtheircommitmentstotheiremployees,customersandbusinesspartners.Followingthistransitionalperiod,bothcompanieshaveconfirmedthatDec.31,2016willbetheofficialclosingdateoftheendoftheirvaccinesjointventureSanofiPasteurMSD(SPMSD),followingclearancesrecentlygrantedbytheEuropeanCommission.“EventhoughDr.Alzheimercharacterizedthediseasein1906,itwasn’tuntilthelastfewdecadesthatthediseasebecamerecognizedasarealillnessseparatefromnormalagingandotherformsofdementia,”saidDarryleSchoepp,Ph.D.,vicepresidentandtherapeuticareahead,Neuroscience,MSD.“Nowpeoplearelivinglonger,andwecanseehowthediseaseworks,”saidDavidMichelson,M.D.,vicepresident,ClinicalNeuroscienceResearch,MSD.“Scienceisataplacewherenotonlydoweunderstandmoreaboutit,butweareexploringwaystodosomethingaboutit.”“Newtechnologiesareallowingtheidentificationofearlydiseasesignswhichwehopewillallowustointervenepromptlyinordertosloworhaltprogression.That’stheholygrail.Whatyouwanttodoistohavesomethingthatworksandtobeabletouseitbeforethediseaserobspeopleofwhotheyreallyare,”saidDr.Michelson.Intheearly1990s,HedyTepplerwastreatingAIDSpatientswithHIV/AIDSatahospitalinPhiladelphia.ShewasalsoservingasaclinicaltrialinvestigatorforPhase1and2MSDstudiesofanewclassofanti-HIVdrugsdesignedtoblocktheHIVproteaseenzymeandthuspreventHIVreplication."Theearlyresultswereexciting.Inashorttime,manypatientsrespondedtotheinvestigationaltreatment,"saysHedy.HerpositiveexperienceduringtheseandsubsequentclinicaltrialswaslargelywhyshejoinedMSDin1996."Iwantedtobemoreinvolvedindrugdevelopmentandclinicaltrialdesign,andMSDwasdoingsomegroundbreakingworkinHIV,"saysHedy,whonowservesasexecutivedirector,ClinicalResearch,InfectiousDiseases,atMSDResearchLaboratories.TheyearbeforeHedyarrived,anotherprominentHIVresearcherandthoughtleaderwaskeepingaclosewatchonMSD'swork.Bach-YenNguyen,nowretired-executivedirector,sectionhead,HCVandHIV,decidedtoleavetheNationalInstitutesofHealthtoworkonMSD'sHIVresearchdevelopmentteam.Bach-YenhadspentyearstreatingAIDSpatientsandworkinginHIVresearchandsawgreatpotentialinMSD'swork."WewerefacedwithanopportunitytohelppatientsinfectedwithHIV."ForBach-Yen,whoalsomadevitalcontributionstothedevelopmentofanotheroneofMSD'smedicinesforthetreatmentofHIV,thedrug'sapprovalcontinuestobehermostmemorablemomentatMSD."Weworkedlonghours.ThereweretimeswhenIcouldn'tattendschooleventswithmyson.WhenpeopleaskedhimwhereIwas,hewouldsay,'MomisbusyhelpingpeoplewithAIDS.'Hewasonly12,butheunderstoodtheimportanceofthework."Withinafewyears,theteamachievedadditionalsuccess:In2011,theFDAapprovedachewabletabletformofthisfirstagentinanewclassofanti-HIVagentsforchildren2yearsandolder,andin2013,approvedgranulesfororalsuspensionforinfants4weeksandolder."Ourpediatricsprogramhasbeenextremelysatisfyingasthereisatremendousneedfornewanti-HIVagentsthatcanbeusedacrosstheentirepediatricagerange,"saysHedy,wholeadstheIsentresspediatricdevelopmentprogram.

  Overthelast20years,MSD’svaccineoperationsinEuropehavebeenpartofajointventurebetweenthecompaniesSanofiandMSD,calledSanofiPasteurMSD(SPMSD).SanofiPasteurMSD—ownedona50/50basisbySanofiPasteurandMSD—wascreatedin1994todevelopandcommercializevaccinesoriginatingfrombothcompanies’pipelinestoimproveandpromotepublichealthin19Europeancountries.Aftercarefullyconsideringourindividualstrategicpriorities,alongsidetheeconomicandregulatoryenvironmentsforvaccineoperationsintheEuropeanUnion,bothcompaniesmutuallyagreedinMarchof2016thatitisinourbestintereststomanageourvaccineproductportfoliosindependently.SanofiPasteurandMSDbelievethatreintegratingtheirrespectivevaccineportfoliosintotheircompanies’operationswillbetterpositionthemtodrivegrowth,executemoreefficiently,optimizevaccinecoverageandbringnewvaccinestomarketmorequickly.Eachcompanywillnowbeabletodefineitsownvaccinesstrategytobenefitpublichealthandcreatevalueforpatients,healthcareprofessionalsandpayers.Throughouttheyear,SPMSDanditsshareholdershavebeenfocusedonasmoothandorderlytransitionwhileachievingtheirpublichealthcaregoalsandupholdingtheircommitmentstotheiremployees,customersandbusinesspartners.Followingthistransitionalperiod,bothcompanieshaveconfirmedthatDec.31,2016willbetheofficialclosingdateoftheendoftheirvaccinesjointventureSanofiPasteurMSD(SPMSD),followingclearancesrecentlygrantedbytheEuropeanCommission.In2016,MSDcelebratedits125thanniversaryasaglobalhealthcareleader.Wecreatedthispageasacelebrationofouraccomplishmentsaswellastohighlightwhatwe'reexcitedaboutfortheyearstocome.Thisisanexcitingtimeforourcompanyandtheworld.Today,weareattheforefrontofinventingtoolsforthefightagainstsomeoftheworld’smosturgentglobalhealthchallenges.Thisincludesmorethan30differentcancers,hepatitisC,Alzheimer’sdisease,Ebola,antibiotic-resistantsuperbugs,cardio-metabolicdiseases,andmanyothers.AfyaSerengetiProjectFormorethan15years,haspartneredwiththe(Afyameans"health"inSwahili)intheSerengetiregionofTanzaniaineasternAfrica.Wehelpprovideaccesstopreventivecare,includingrabiesvaccinationsforlocaldogs.Todate,wehavedonatedtwomillionrabiesvaccinestosupportprogramsinIndia,Malawi,SriLanka,TanzaniaandUganda.Wealsoprovidetoolssuchasall-terrainvehiclesandtentstohelpmakesuretheprojectisabletoreachthemostremotecornersoftheregion.Rabiesinhumansanddomesticanimalshasnowbeenvirtuallyeliminatedfromthisareaandhumanhospitalizationsduetorabiddogbiteshavedecreased92percent.

  In1987,MSD’sthenCEODr.P.RoyVagelosannounced,inanunprecedentedactofglobalhealthcareleadership,thatMSDwoulddonateivermectin–asmuchasneededforaslongasneeded–withthegoaltohelpeliminateriverblindness.MSDrecognizedinordertoreachthisgoal,manyorganizationswithuniqueskillswouldneedtoworktogetherasateam.Asaresult,MSDcreatedtheMectizanDonationProgram(MDP).OperatingfromtheAtlanta-basedTaskForceforGlobalHealth,theMDPcoordinatesactivitiesbetweenMSD,WHO,theWorldBankandarangeofpublicandprivatestakeholders.In1998,MSDexpandeditscommitmentfromtheMectizanDonationProgramtoincludedonatingivermectinforanotherdisease,lymphaticfilariasis(LF),alsoknownaselephantiasis,inAfricancountriesandYemenwhereitco-existswithriverblindness.ForLF,ivermectinisadministeredwithalbendazole,adrugdonatedbyGSK.Antibioticshaverevolutionizedmedicineinmanyrespects,andcountlessliveshavebeensaved;theirdiscoverywasaturningpointinhumanhistory.Foralmostacentury,bacteria-fightingdrugsknownasantibioticshavehelpedtomanagemanyoftheharmfulbacteriathatcanmakeussick.Butinrecentdecades,theyhavebecomelesseffectiveagainstsometypesofbacteria.Currently,certainbacteriaarenowunbeatablewithtoday’smedicines.Unfortunately,newdrug-resistant“superbugs”haveemerged,whicharestrainsofbacteriathatareresistanttoseveraltypesofantibiotics.Infact,theWorldHealthOrganizationhasclassifiedthisas“aseriousthreat[that]isnolongerapredictionforthefuture,itishappeningrightnowineveryregionoftheworldandhasthepotentialtoaffectanyone,ofanyage,inanycountry.”Ourdiscoveryscientists“strivetomaketheimpossiblepossible,”saysJoeMiletich.Andheshouldknow:AstheseniorvicepresidentofDiscoveryPreclinicalandEarlyDevelopment,heleadsateamofresearcherswhoarechargedwithmakingthings“possiblethatweren’tpossiblebefore.”Hecontinues:“Webelievedrugdiscoveryisfoundationalforustocontinuebringingcriticalmedicinestotheworld.”About14,500peopleareinvolvedinscientificresearchatMSD.OurRDcolleaguesarealltaskedwiththesamemission:tosolvethepuzzlesofhumandiseasebiologyandthentranslatethosefindingsintonewtherapiesforpatients.Theyaredriventopushtheboundariesofscienceandtothentransformtheirdiscoveriesintomeaningfulnewtherapeutics.

  Overthepast125years,we’veseentheworldchangethroughthepowerofmedicineandinvention.Whileeachpivotalmilestonehasbeenunique,onethingtheyhaveincommonisthatwehaven’tdoneitalone.AtMSD,wehavealwaysbelievedthatgreatmedicalbreakthroughsrelyonteamwork–fromwithinandoutsideofMSD–andourhistoryhasprovenit.Weareproudtohaveworkedinpartnershipwithcompanies,academics,governments,patientorganizations,healthcareprofessionals,nongovernmentalorganizations(NGOs),multilateralorganizationsandothersintheprivatesector--tohelpimprovelivesaroundtheworldandcontinuetosolvesomeoftheworld’smostseriousillnesses.TheImpactofStigmatizationThesenorms,behaviors,andbeliefssurroundinghepatitisCinfectioncanleadtoalienationfromfamilyandfriends,aswellastodiscrimination(perceivedorreal)inhealthservicesandworkplaces.Indeed,manychronichepatitisCpatientsreportfeelingsofstigmatizationandsocialisolationfromtheirfriends,family,andcoworkers.WevetalkedtoHCVinfectedgrandmotherswhoseownchildrenwon’tallowthemtoplaywiththeirgrandchildrenbecausethey’reafraidofsomesortoftransmission,reportsMichaelNinburg,executivedirectoroftheHepatitisEducationProject,aSeattle-basedgroupfoundedin1993toprovideeducation,support,andadvocacyforthoselivingwithhepatitis.ArecentlydiagnosedpatientwhoworkswithMichael’sgroupechoedthissentiment.I'msuperoutgoing.ItalkabouteveryfeelingIhavetomyfriends,justaboutanybody,andmydiagnosiswassomethingIcouldnottalkabout,hesaid.IknewthatIhadtodosomethingaboutit,butIwasashamed.TheImpactofStigmatizationThesenorms,behaviors,andbeliefssurroundinghepatitisCinfectioncanleadtoalienationfromfamilyandfriends,aswellastodiscrimination(perceivedorreal)inhealthservicesandworkplaces.Indeed,manychronichepatitisCpatientsreportfeelingsofstigmatizationandsocialisolationfromtheirfriends,family,andcoworkers.WevetalkedtoHCVinfectedgrandmotherswhoseownchildrenwon’tallowthemtoplaywiththeirgrandchildrenbecausethey’reafraidofsomesortoftransmission,reportsMichaelNinburg,executivedirectoroftheHepatitisEducationProject,aSeattle-basedgroupfoundedin1993toprovideeducation,support,andadvocacyforthoselivingwithhepatitis.ArecentlydiagnosedpatientwhoworkswithMichael’sgroupechoedthissentiment.I'msuperoutgoing.ItalkabouteveryfeelingIhavetomyfriends,justaboutanybody,andmydiagnosiswassomethingIcouldnottalkabout,hesaid.IknewthatIhadtodosomethingaboutit,butIwasashamed.

  Overthelast20years,MSD’svaccineoperationsinEuropehavebeenpartofajointventurebetweenthecompaniesSanofiandMSD,calledSanofiPasteurMSD(SPMSD).SanofiPasteurMSD—ownedona50/50basisbySanofiPasteurandMSD—wascreatedin1994todevelopandcommercializevaccinesoriginatingfrombothcompanies’pipelinestoimproveandpromotepublichealthin19Europeancountries.Aftercarefullyconsideringourindividualstrategicpriorities,alongsidetheeconomicandregulatoryenvironmentsforvaccineoperationsintheEuropeanUnion,bothcompaniesmutuallyagreedinMarchof2016thatitisinourbestintereststomanageourvaccineproductportfoliosindependently.SanofiPasteurandMSDbelievethatreintegratingtheirrespectivevaccineportfoliosintotheircompanies’operationswillbetterpositionthemtodrivegrowth,executemoreefficiently,optimizevaccinecoverageandbringnewvaccinestomarketmorequickly.Eachcompanywillnowbeabletodefineitsownvaccinesstrategytobenefitpublichealthandcreatevalueforpatients,healthcareprofessionalsandpayers.Throughouttheyear,SPMSDanditsshareholdershavebeenfocusedonasmoothandorderlytransitionwhileachievingtheirpublichealthcaregoalsandupholdingtheircommitmentstotheiremployees,customersandbusinesspartners.Followingthistransitionalperiod,bothcompanieshaveconfirmedthatDec.31,2016willbetheofficialclosingdateoftheendoftheirvaccinesjointventureSanofiPasteurMSD(SPMSD),followingclearancesrecentlygrantedbytheEuropeanCommission.Intheearly1990s,HedyTepplerwastreatingAIDSpatientswithHIV/AIDSatahospitalinPhiladelphia.ShewasalsoservingasaclinicaltrialinvestigatorforPhase1and2MSDstudiesofanewclassofanti-HIVdrugsdesignedtoblocktheHIVproteaseenzymeandthuspreventHIVreplication."Theearlyresultswereexciting.Inashorttime,manypatientsrespondedtotheinvestigationaltreatment,"saysHedy.HerpositiveexperienceduringtheseandsubsequentclinicaltrialswaslargelywhyshejoinedMSDin1996."Iwantedtobemoreinvolvedindrugdevelopmentandclinicaltrialdesign,andMSDwasdoingsomegroundbreakingworkinHIV,"saysHedy,whonowservesasexecutivedirector,ClinicalResearch,InfectiousDiseases,atMSDResearchLaboratories.TheyearbeforeHedyarrived,anotherprominentHIVresearcherandthoughtleaderwaskeepingaclosewatchonMSD'swork.Bach-YenNguyen,nowretired-executivedirector,sectionhead,HCVandHIV,decidedtoleavetheNationalInstitutesofHealthtoworkonMSD'sHIVresearchdevelopmentteam.Bach-YenhadspentyearstreatingAIDSpatientsandworkinginHIVresearchandsawgreatpotentialinMSD'swork."WewerefacedwithanopportunitytohelppatientsinfectedwithHIV."ForBach-Yen,whoalsomadevitalcontributionstothedevelopmentofanotheroneofMSD'smedicinesforthetreatmentofHIV,thedrug'sapprovalcontinuestobehermostmemorablemomentatMSD."Weworkedlonghours.ThereweretimeswhenIcouldn'tattendschooleventswithmyson.WhenpeopleaskedhimwhereIwas,hewouldsay,'MomisbusyhelpingpeoplewithAIDS.'Hewasonly12,butheunderstoodtheimportanceofthework."Withinafewyears,theteamachievedadditionalsuccess:In2011,theFDAapprovedachewabletabletformofthisfirstagentinanewclassofanti-HIVagentsforchildren2yearsandolder,andin2013,approvedgranulesfororalsuspensionforinfants4weeksandolder."Ourpediatricsprogramhasbeenextremelysatisfyingasthereisatremendousneedfornewanti-HIVagentsthatcanbeusedacrosstheentirepediatricagerange,"saysHedy,wholeadstheIsentresspediatricdevelopmentprogram.Ourdiscoveryscientists“strivetomaketheimpossiblepossible,”saysJoeMiletich.Andheshouldknow:AstheseniorvicepresidentofDiscoveryPreclinicalandEarlyDevelopment,heleadsateamofresearcherswhoarechargedwithmakingthings“possiblethatweren’tpossiblebefore.”Hecontinues:“Webelievedrugdiscoveryisfoundationalforustocontinuebringingcriticalmedicinestotheworld.”About14,500peopleareinvolvedinscientificresearchatMSD.OurRDcolleaguesarealltaskedwiththesamemission:tosolvethepuzzlesofhumandiseasebiologyandthentranslatethosefindingsintonewtherapiesforpatients.Theyaredriventopushtheboundariesofscienceandtothentransformtheirdiscoveriesintomeaningfulnewtherapeutics.

  In2016,MSDcelebratedits125thanniversaryasaglobalhealthcareleader.Wecreatedthispageasacelebrationofouraccomplishmentsaswellastohighlightwhatwe'reexcitedaboutfortheyearstocome.Thisisanexcitingtimeforourcompanyandtheworld.Today,weareattheforefrontofinventingtoolsforthefightagainstsomeoftheworld’smosturgentglobalhealthchallenges.Thisincludesmorethan30differentcancers,hepatitisC,Alzheimer’sdisease,Ebola,antibiotic-resistantsuperbugs,cardio-metabolicdiseases,andmanyothers.“EventhoughDr.Alzheimercharacterizedthediseasein1906,itwasn’tuntilthelastfewdecadesthatthediseasebecamerecognizedasarealillnessseparatefromnormalagingandotherformsofdementia,”saidDarryleSchoepp,Ph.D.,vicepresidentandtherapeuticareahead,Neuroscience,MSD.“Nowpeoplearelivinglonger,andwecanseehowthediseaseworks,”saidDavidMichelson,M.D.,vicepresident,ClinicalNeuroscienceResearch,MSD.“Scienceisataplacewherenotonlydoweunderstandmoreaboutit,butweareexploringwaystodosomethingaboutit.”“Newtechnologiesareallowingtheidentificationofearlydiseasesignswhichwehopewillallowustointervenepromptlyinordertosloworhaltprogression.That’stheholygrail.Whatyouwanttodoistohavesomethingthatworksandtobeabletouseitbeforethediseaserobspeopleofwhotheyreallyare,”saidDr.Michelson.Overthepast125years,we’veseentheworldchangethroughthepowerofmedicineandinvention.Whileeachpivotalmilestonehasbeenunique,onethingtheyhaveincommonisthatwehaven’tdoneitalone.AtMSD,wehavealwaysbelievedthatgreatmedicalbreakthroughsrelyonteamwork–fromwithinandoutsideofMSD–andourhistoryhasprovenit.Weareproudtohaveworkedinpartnershipwithcompanies,academics,governments,patientorganizations,healthcareprofessionals,nongovernmentalorganizations(NGOs),multilateralorganizationsandothersintheprivatesector--tohelpimprovelivesaroundtheworldandcontinuetosolvesomeoftheworld’smostseriousillnesses.

  Overthelast20years,MSD’svaccineoperationsinEuropehavebeenpartofajointventurebetweenthecompaniesSanofiandMSD,calledSanofiPasteurMSD(SPMSD).SanofiPasteurMSD—ownedona50/50basisbySanofiPasteurandMSD—wascreatedin1994todevelopandcommercializevaccinesoriginatingfrombothcompanies’pipelinestoimproveandpromotepublichealthin19Europeancountries.Aftercarefullyconsideringourindividualstrategicpriorities,alongsidetheeconomicandregulatoryenvironmentsforvaccineoperationsintheEuropeanUnion,bothcompaniesmutuallyagreedinMarchof2016thatitisinourbestintereststomanageourvaccineproductportfoliosindependently.SanofiPasteurandMSDbelievethatreintegratingtheirrespectivevaccineportfoliosintotheircompanies’operationswillbetterpositionthemtodrivegrowth,executemoreefficiently,optimizevaccinecoverageandbringnewvaccinestomarketmorequickly.Eachcompanywillnowbeabletodefineitsownvaccinesstrategytobenefitpublichealthandcreatevalueforpatients,healthcareprofessionalsandpayers.Throughouttheyear,SPMSDanditsshareholdershavebeenfocusedonasmoothandorderlytransitionwhileachievingtheirpublichealthcaregoalsandupholdingtheircommitmentstotheiremployees,customersandbusinesspartners.Followingthistransitionalperiod,bothcompanieshaveconfirmedthatDec.31,2016willbetheofficialclosingdateoftheendoftheirvaccinesjointventureSanofiPasteurMSD(SPMSD),followingclearancesrecentlygrantedbytheEuropeanCommission.AfyaSerengetiProjectFormorethan15years,haspartneredwiththe(Afyameans"health"inSwahili)intheSerengetiregionofTanzaniaineasternAfrica.Wehelpprovideaccesstopreventivecare,includingrabiesvaccinationsforlocaldogs.Todate,wehavedonatedtwomillionrabiesvaccinestosupportprogramsinIndia,Malawi,SriLanka,TanzaniaandUganda.Wealsoprovidetoolssuchasall-terrainvehiclesandtentstohelpmakesuretheprojectisabletoreachthemostremotecornersoftheregion.Rabiesinhumansanddomesticanimalshasnowbeenvirtuallyeliminatedfromthisareaandhumanhospitalizationsduetorabiddogbiteshavedecreased92percent.TheMSDFellowshipforGlobalHealthisonewayMSDishelpinganswertheglobalhealthneedsoftheunderserved.MSDemployeeswhoparticipateintheprogramarecalledRichardT.ClarkFellows(RTCFellows)inhonorofretiredChairmanandCEORichardT.Clarkandhisphilosophyofpassion,purposeandcommitmenttocorporateresponsibility.Launchedin2012,theprogramoffersMSDemployeesopportunitiestosharetheirskillswithpeoplearoundtheworld.Asmanyas30Fellowsareselectedeachyear;theexpertiseoftheapplicantsismatchedtotheneedsofthepartnerorganizations.Duringthethree-monthassignments,theFellowsareembeddedwithinanon-profitorganizationinthefield.

  Overthepast125years,we’veseentheworldchangethroughthepowerofmedicineandinvention.Whileeachpivotalmilestonehasbeenunique,onethingtheyhaveincommonisthatwehaven’tdoneitalone.AtMSD,wehavealwaysbelievedthatgreatmedicalbreakthroughsrelyonteamwork–fromwithinandoutsideofMSD–andourhistoryhasprovenit.Weareproudtohaveworkedinpartnershipwithcompanies,academics,governments,patientorganizations,healthcareprofessionals,nongovernmentalorganizations(NGOs),multilateralorganizationsandothersintheprivatesector--tohelpimprovelivesaroundtheworldandcontinuetosolvesomeoftheworld’smostseriousillnesses.In1987,MSD’sthenCEODr.P.RoyVagelosannounced,inanunprecedentedactofglobalhealthcareleadership,thatMSDwoulddonateivermectin–asmuchasneededforaslongasneeded–withthegoaltohelpeliminateriverblindness.MSDrecognizedinordertoreachthisgoal,manyorganizationswithuniqueskillswouldneedtoworktogetherasateam.Asaresult,MSDcreatedtheMectizanDonationProgram(MDP).OperatingfromtheAtlanta-basedTaskForceforGlobalHealth,theMDPcoordinatesactivitiesbetweenMSD,WHO,theWorldBankandarangeofpublicandprivatestakeholders.In1998,MSDexpandeditscommitmentfromtheMectizanDonationProgramtoincludedonatingivermectinforanotherdisease,lymphaticfilariasis(LF),alsoknownaselephantiasis,inAfricancountriesandYemenwhereitco-existswithriverblindness.ForLF,ivermectinisadministeredwithalbendazole,adrugdonatedbyGSK.Overthelast20years,MSD’svaccineoperationsinEuropehavebeenpartofajointventurebetweenthecompaniesSanofiandMSD,calledSanofiPasteurMSD(SPMSD).SanofiPasteurMSD—ownedona50/50basisbySanofiPasteurandMSD—wascreatedin1994todevelopandcommercializevaccinesoriginatingfrombothcompanies’pipelinestoimproveandpromotepublichealthin19Europeancountries.Aftercarefullyconsideringourindividualstrategicpriorities,alongsidetheeconomicandregulatoryenvironmentsforvaccineoperationsintheEuropeanUnion,bothcompaniesmutuallyagreedinMarchof2016thatitisinourbestintereststomanageourvaccineproductportfoliosindependently.SanofiPasteurandMSDbelievethatreintegratingtheirrespectivevaccineportfoliosintotheircompanies’operationswillbetterpositionthemtodrivegrowth,executemoreefficiently,optimizevaccinecoverageandbringnewvaccinestomarketmorequickly.Eachcompanywillnowbeabletodefineitsownvaccinesstrategytobenefitpublichealthandcreatevalueforpatients,healthcareprofessionalsandpayers.Throughouttheyear,SPMSDanditsshareholdershavebeenfocusedonasmoothandorderlytransitionwhileachievingtheirpublichealthcaregoalsandupholdingtheircommitmentstotheiremployees,customersandbusinesspartners.Followingthistransitionalperiod,bothcompanieshaveconfirmedthatDec.31,2016willbetheofficialclosingdateoftheendoftheirvaccinesjointventureSanofiPasteurMSD(SPMSD),followingclearancesrecentlygrantedbytheEuropeanCommission.

  Overthelast20years,MSD’svaccineoperationsinEuropehavebeenpartofajointventurebetweenthecompaniesSanofiandMSD,calledSanofiPasteurMSD(SPMSD).SanofiPasteurMSD—ownedona50/50basisbySanofiPasteurandMSD—wascreatedin1994todevelopandcommercializevaccinesoriginatingfrombothcompanies’pipelinestoimproveandpromotepublichealthin19Europeancountries.Aftercarefullyconsideringourindividualstrategicpriorities,alongsidetheeconomicandregulatoryenvironmentsforvaccineoperationsintheEuropeanUnion,bothcompaniesmutuallyagreedinMarchof2016thatitisinourbestintereststomanageourvaccineproductportfoliosindependently.SanofiPasteurandMSDbelievethatreintegratingtheirrespectivevaccineportfoliosintotheircompanies’operationswillbetterpositionthemtodrivegrowth,executemoreefficiently,optimizevaccinecoverageandbringnewvaccinestomarketmorequickly.Eachcompanywillnowbeabletodefineitsownvaccinesstrategytobenefitpublichealthandcreatevalueforpatients,healthcareprofessionalsandpayers.Throughouttheyear,SPMSDanditsshareholdershavebeenfocusedonasmoothandorderlytransitionwhileachievingtheirpublichealthcaregoalsandupholdingtheircommitmentstotheiremployees,customersandbusinesspartners.Followingthistransitionalperiod,bothcompanieshaveconfirmedthatDec.31,2016willbetheofficialclosingdateoftheendoftheirvaccinesjointventureSanofiPasteurMSD(SPMSD),followingclearancesrecentlygrantedbytheEuropeanCommission.ELIAV:HCV[hepatitisCvirus]infectionisablood-bornedisease.Peoplebecomeinfectedwhenexposedtocontaminatedbloodproductsorcontaminatedsyringesorinjectionequipment.TheincidenceofHCVinfection(thenknownasnon-A/non-Bhepatitis)priorto1965waslow;however,therateincreasedsteadilyintothe1980s.In1988,HCVwasidentifiedandbloodsupplyscreeningforHCVbecameavailablein1992.Peoplegotinfectedandusuallydidn'tknowitbecausetheacuteinfectionistypicallyasymptomatic.Afterprolongedinfection,20to25years,orso,peoplewerepresentingwithadvancedliverdamage,whichcanleadtocirrhosisandeventuallyevenliverfailureorlivercancer.Ahugecohortofbabyboomersgotinfected,didn'tknowit,aregraduallygettingdiagnosedandfindingtheirdiseaseissoadvancedthattheyareapproachingacrisispoint.Theclockistickingonthisproblem.In1987,MSD’sthenCEODr.P.RoyVagelosannounced,inanunprecedentedactofglobalhealthcareleadership,thatMSDwoulddonateivermectin–asmuchasneededforaslongasneeded–withthegoaltohelpeliminateriverblindness.MSDrecognizedinordertoreachthisgoal,manyorganizationswithuniqueskillswouldneedtoworktogetherasateam.Asaresult,MSDcreatedtheMectizanDonationProgram(MDP).OperatingfromtheAtlanta-basedTaskForceforGlobalHealth,theMDPcoordinatesactivitiesbetweenMSD,WHO,theWorldBankandarangeofpublicandprivatestakeholders.In1998,MSDexpandeditscommitmentfromtheMectizanDonationProgramtoincludedonatingivermectinforanotherdisease,lymphaticfilariasis(LF),alsoknownaselephantiasis,inAfricancountriesandYemenwhereitco-existswithriverblindness.ForLF,ivermectinisadministeredwithalbendazole,adrugdonatedbyGSK.

  TheMSDFellowshipforGlobalHealthisonewayMSDishelpinganswertheglobalhealthneedsoftheunderserved.MSDemployeeswhoparticipateintheprogramarecalledRichardT.ClarkFellows(RTCFellows)inhonorofretiredChairmanandCEORichardT.Clarkandhisphilosophyofpassion,purposeandcommitmenttocorporateresponsibility.Launchedin2012,theprogramoffersMSDemployeesopportunitiestosharetheirskillswithpeoplearoundtheworld.Asmanyas30Fellowsareselectedeachyear;theexpertiseoftheapplicantsismatchedtotheneedsofthepartnerorganizations.Duringthethree-monthassignments,theFellowsareembeddedwithinanon-profitorganizationinthefield.“EventhoughDr.Alzheimercharacterizedthediseasein1906,itwasn’tuntilthelastfewdecadesthatthediseasebecamerecognizedasarealillnessseparatefromnormalagingandotherformsofdementia,”saidDarryleSchoepp,Ph.D.,vicepresidentandtherapeuticareahead,Neuroscience,MSD.“Nowpeoplearelivinglonger,andwecanseehowthediseaseworks,”saidDavidMichelson,M.D.,vicepresident,ClinicalNeuroscienceResearch,MSD.“Scienceisataplacewherenotonlydoweunderstandmoreaboutit,butweareexploringwaystodosomethingaboutit.”“Newtechnologiesareallowingtheidentificationofearlydiseasesignswhichwehopewillallowustointervenepromptlyinordertosloworhaltprogression.That’stheholygrail.Whatyouwanttodoistohavesomethingthatworksandtobeabletouseitbeforethediseaserobspeopleofwhotheyreallyare,”saidDr.Michelson.HbA1c,ameasureoftheaveragelevelofbloodsugaroverthepasttwotothreemonths,helpsyouandyourdoctorseehowwellyourdiabetestreatmentplanisworking.TherecommendedHbA1c,goalformanyadultswithtype2diabetesislessthan7%;however,thismayvarydependingontheindividual.Highbloodsugarlevelsovertimecanputpeoplewithdiabetesatriskofmanyserioushealthproblems,suchasheartdisease,stroke,kidneydisease,blindnessandnerveproblems.That’swhyitisimportantforpeoplelivingwithdiabetestoworkwiththeirdoctortosetindividualizedgoalsanddevelopapersonalizeddiabetesmanagementplantomanagetheABCsofdiabetes:AforHbA1c,BforbloodpressureandCforcholesterol.

  TheImpactofStigmatizationThesenorms,behaviors,andbeliefssurroundinghepatitisCinfectioncanleadtoalienationfromfamilyandfriends,aswellastodiscrimination(perceivedorreal)inhealthservicesandworkplaces.Indeed,manychronichepatitisCpatientsreportfeelingsofstigmatizationandsocialisolationfromtheirfriends,family,andcoworkers.WevetalkedtoHCVinfectedgrandmotherswhoseownchildrenwon’tallowthemtoplaywiththeirgrandchildrenbecausethey’reafraidofsomesortoftransmission,reportsMichaelNinburg,executivedirectoroftheHepatitisEducationProject,aSeattle-basedgroupfoundedin1993toprovideeducation,support,andadvocacyforthoselivingwithhepatitis.ArecentlydiagnosedpatientwhoworkswithMichael’sgroupechoedthissentiment.I'msuperoutgoing.ItalkabouteveryfeelingIhavetomyfriends,justaboutanybody,andmydiagnosiswassomethingIcouldnottalkabout,hesaid.IknewthatIhadtodosomethingaboutit,butIwasashamed.Overthepast125years,we’veseentheworldchangethroughthepowerofmedicineandinvention.Whileeachpivotalmilestonehasbeenunique,onethingtheyhaveincommonisthatwehaven’tdoneitalone.AtMSD,wehavealwaysbelievedthatgreatmedicalbreakthroughsrelyonteamwork–fromwithinandoutsideofMSD–andourhistoryhasprovenit.Weareproudtohaveworkedinpartnershipwithcompanies,academics,governments,patientorganizations,healthcareprofessionals,nongovernmentalorganizations(NGOs),multilateralorganizationsandothersintheprivatesector--tohelpimprovelivesaroundtheworldandcontinuetosolvesomeoftheworld’smostseriousillnesses.Intheearly1990s,HedyTepplerwastreatingAIDSpatientswithHIV/AIDSatahospitalinPhiladelphia.ShewasalsoservingasaclinicaltrialinvestigatorforPhase1and2MSDstudiesofanewclassofanti-HIVdrugsdesignedtoblocktheHIVproteaseenzymeandthuspreventHIVreplication."Theearlyresultswereexciting.Inashorttime,manypatientsrespondedtotheinvestigationaltreatment,"saysHedy.HerpositiveexperienceduringtheseandsubsequentclinicaltrialswaslargelywhyshejoinedMSDin1996."Iwantedtobemoreinvolvedindrugdevelopmentandclinicaltrialdesign,andMSDwasdoingsomegroundbreakingworkinHIV,"saysHedy,whonowservesasexecutivedirector,ClinicalResearch,InfectiousDiseases,atMSDResearchLaboratories.TheyearbeforeHedyarrived,anotherprominentHIVresearcherandthoughtleaderwaskeepingaclosewatchonMSD'swork.Bach-YenNguyen,nowretired-executivedirector,sectionhead,HCVandHIV,decidedtoleavetheNationalInstitutesofHealthtoworkonMSD'sHIVresearchdevelopmentteam.Bach-YenhadspentyearstreatingAIDSpatientsandworkinginHIVresearchandsawgreatpotentialinMSD'swork."WewerefacedwithanopportunitytohelppatientsinfectedwithHIV."ForBach-Yen,whoalsomadevitalcontributionstothedevelopmentofanotheroneofMSD'smedicinesforthetreatmentofHIV,thedrug'sapprovalcontinuestobehermostmemorablemomentatMSD."Weworkedlonghours.ThereweretimeswhenIcouldn'tattendschooleventswithmyson.WhenpeopleaskedhimwhereIwas,hewouldsay,'MomisbusyhelpingpeoplewithAIDS.'Hewasonly12,butheunderstoodtheimportanceofthework."Withinafewyears,theteamachievedadditionalsuccess:In2011,theFDAapprovedachewabletabletformofthisfirstagentinanewclassofanti-HIVagentsforchildren2yearsandolder,andin2013,approvedgranulesfororalsuspensionforinfants4weeksandolder."Ourpediatricsprogramhasbeenextremelysatisfyingasthereisatremendousneedfornewanti-HIVagentsthatcanbeusedacrosstheentirepediatricagerange,"saysHedy,wholeadstheIsentresspediatricdevelopmentprogram.

  In1987,MSD’sthenCEODr.P.RoyVagelosannounced,inanunprecedentedactofglobalhealthcareleadership,thatMSDwoulddonateivermectin–asmuchasneededforaslongasneeded–withthegoaltohelpeliminateriverblindness.MSDrecognizedinordertoreachthisgoal,manyorganizationswithuniqueskillswouldneedtoworktogetherasateam.Asaresult,MSDcreatedtheMectizanDonationProgram(MDP).OperatingfromtheAtlanta-basedTaskForceforGlobalHealth,theMDPcoordinatesactivitiesbetweenMSD,WHO,theWorldBankandarangeofpublicandprivatestakeholders.In1998,MSDexpandeditscommitmentfromtheMectizanDonationProgramtoincludedonatingivermectinforanotherdisease,lymphaticfilariasis(LF),alsoknownaselephantiasis,inAfricancountriesandYemenwhereitco-existswithriverblindness.ForLF,ivermectinisadministeredwithalbendazole,adrugdonatedbyGSK.Ourdiscoveryscientists“strivetomaketheimpossiblepossible,”saysJoeMiletich.Andheshouldknow:AstheseniorvicepresidentofDiscoveryPreclinicalandEarlyDevelopment,heleadsateamofresearcherswhoarechargedwithmakingthings“possiblethatweren’tpossiblebefore.”Hecontinues:“Webelievedrugdiscoveryisfoundationalforustocontinuebringingcriticalmedicinestotheworld.”About14,500peopleareinvolvedinscientificresearchatMSD.OurRDcolleaguesarealltaskedwiththesamemission:tosolvethepuzzlesofhumandiseasebiologyandthentranslatethosefindingsintonewtherapiesforpatients.Theyaredriventopushtheboundariesofscienceandtothentransformtheirdiscoveriesintomeaningfulnewtherapeutics.ELIAV:HCV[hepatitisCvirus]infectionisablood-bornedisease.Peoplebecomeinfectedwhenexposedtocontaminatedbloodproductsorcontaminatedsyringesorinjectionequipment.TheincidenceofHCVinfection(thenknownasnon-A/non-Bhepatitis)priorto1965waslow;however,therateincreasedsteadilyintothe1980s.In1988,HCVwasidentifiedandbloodsupplyscreeningforHCVbecameavailablein1992.Peoplegotinfectedandusuallydidn'tknowitbecausetheacuteinfectionistypicallyasymptomatic.Afterprolongedinfection,20to25years,orso,peoplewerepresentingwithadvancedliverdamage,whichcanleadtocirrhosisandeventuallyevenliverfailureorlivercancer.Ahugecohortofbabyboomersgotinfected,didn'tknowit,aregraduallygettingdiagnosedandfindingtheirdiseaseissoadvancedthattheyareapproachingacrisispoint.Theclockistickingonthisproblem.

责任编辑:www.tyc66.com_www.tyc66.com-【会员注册】社友网:未经授权不得转载
关键词 >>

继续阅读

热新闻

热话题

热门推荐

关于我们 联系我们 版权声明 网站地图
百站百胜: 上市前业绩增长放缓中国飞鹤的三大财务疑点 15岁少女被拐骗强迫卖淫长达十年保护伞被打掉 二胎概念拉升邦宝益智涨停 智利总统宣布改组内阁全国大部分地区结束宵禁 德国11月份消费者信心先行指数降至三年来新低 市长一声令下首尔全面停止屠狗 澳门经济财政司司长:正研究建立证券市场的可行性 优爱腾联合六影视公司倡议:加强行业自律促健康发展 汪东进升任中国海油董事长 苏州国宇收购案亮绿灯大烨智能重组获有条件通过 中学当众销毁收缴的学生手机负责人:为了孩子好 罗辑思维拟科创板上市符合“逻辑”吗? 海通期货:持续去库阶段下乙二醇逢低做多报告 套房源一日抢光全国首批 口香糖销量降一成背后:罗汉堂GDP没告诉你的9个真相 云南白药打工业大麻擦边球“输血”万隆控股 中国重汽董事长:所有领导干部办公室的沙发全部取缔 环球时报:政治进赛场这回轮到西方暴怒了 天弘基金换帅蚂蚁金服总裁胡晓明接棒 日本小车撞入咖啡馆致9伤75岁肇事者被当场逮捕 用超募资金投资且未及时披露南大光电被出具警示函 铁矿巨头淡水河谷复产后业绩好转推进溃坝事件赔偿 宁夏青铜峡:对信访举报信实行编码管理 德国防长提议北约在叙设安全区拉上土俄共同参与 李迅雷:无风险利率下行有利于提升核心资产估值 券商招聘首席分析师重排名更重创收能力 OPEC+减产难掩需求低迷谨防EIA原油库存连涨六周 多地楼市政策“松绑”专家称限购不可能完全取消 新华社:英欧“脱欧”新协议通过前景不容乐观 港媒:律政司申请禁滋扰警察宿舍禁制令获通过 原油基本面仍未改善 乐视熄火游侠停摆蔚来折戟 俄罗斯防长在北京香山论坛向美国“开炮” 下游钢铁业回款好濮耐股份第三季净利同比增60.43% 中青报:年轻人不胡吃海喝就是“低欲望”了? 调研一线:浙商银行王长山金融扶贫背后的故事 英媒:至少6个越南家庭或有亲人在货车内 称一小行星下月与地球 英国议长泪崩:我们应该愉快地求同存异 王俊:一个剧一个综艺火不火关键在于有没有创造热词 浙江丽水原副市长林康案开庭:被诉受贿超4196万元 分拆20年后南船北船终合体“中国神船”正式启航 匈牙利%若土放难民匈方将以武力保护欧盟 AMD锐龙73750X首次曝光:超频小王子? 51信用卡旗下上海公司“人去楼空” 菲律宾拟对电子烟大幅加税 邓普顿基金明星经理失手旗舰债基三个月亏30亿美元 隆鑫通用控股股东遇资金链危机3.8亿股股权质押违约 英欧脱欧协议达成仍需欧洲议会和欧洲理事会批准 编制CPI时对猪肉权重有人为调整?国家统计局释疑 太残忍印度男子在墓地发现新生女婴被活埋 女子啃了一口苹果5分钟后被送到ICU紧急抢救 抑郁症患者全球超3.5亿人职场人群成“主力” 荣耀智慧屏首次官方大降价:跌破3000 几千里之外的这场战事让中国网友感慨良多 监管部门批准特斯拉将开始在上海工厂生产Model3 从完美女神到“碰瓷大王”江一燕踏错了哪一步? 阿里巴巴张勇谈新商业文明:让更多小草长成参天大树 罢工延长!通用汽车因停工已损失约20亿美元 航天通信:子公司违规担保3.68亿美元担保合同解除 河北兴华钢铁起火7人死亡曾被评为安全生产先进企业 携号转网已办成290万人次11月底前全国范围正式实施 全球产业“空窗期”数字科技的想象空间在哪 中国奥委会纪念重返国际奥林匹克大家庭40年 国内首款商业防贫险成绩单:已为5000万临贫 距公布利率决议不到2周美联储决策者降息持开放态度 龙头股走势强劲人造肉板块卷土重来 朗源股份增资丰佑布局工业大麻标的今年4月成立 江苏多企业二次回购爱康科技股份回购成空头支票 爆款基金再现:睿远抢购埋下伏笔百亿私募收益可观 韩国国防部组织军民近千人联合捕野猪:防猪瘟 杭州萧山一黑社会性质组织案组织者被判刑24年 蒙牛低调试水新品牌“甄简”加快布局大健康产业 四大证券报头版内容精华摘要 苹果供应格局宽松后市价格难有起色 白宫:将向叙利亚“白头盔”组织资助450万美元 河北三河新集中学学生肠胃不适排除人为破坏可能 激发并购重组活力促进上市公司提高质量实招连出 今年我国社保降费已达2725亿元其中9月减费477亿元 港龙地产、三巽集团赴港求上市小房企急切图生 首批受理企业利元亨主动撤回科创板申请未披露原因 证监会:深化境外上市制度改革服务H股公司健康发展 公安部发文:封停中缅边境部分地区微信、支付宝 银行给死人办了ETC回应:搞错了车牌类型已注销 现代汽车第三季度净利润低于预期中国市场表现不佳 绿景控股卖无可卖成壳股股权转让款被欠业绩堪忧 全国首个老人鞋团体标准出台对鞋企“立规矩” 青岛海关出台5方面17项措施推动形成开放格局 5G的成熟将促进产业升级和融合开创数字经济新时代 广东、江苏前三季度GDP超7万亿16省份增速跑赢全国 银行级“刷脸付”来了宁波、杭州等地将率先享用 WeWork折戟IPO共享办公遇坎 深冷股份:股东无锡楚祥及其一致人拟减持不超过6% 华为王成录:未来体验创新将会围绕IoT全场景 花3万学英语想中途退课“退费”引出培训费贷款迷局 利好将尽EG关注趋势做空机会 全国人大常委会会议今日召开将审议多部法律草案 大和:世茂房地产目标价升至29.1港元维持买入评级 解放军飞行员执行训练任务时牺牲曾参加九三阅兵 21批次燃气灶被检出不合格松下厨卫欧普等上榜 70年来中国人口变迁:每6个人中至少有1个流动人口 聚焦乌镇峰会:尽览大咖动态、会议议程、专家声音 中超职业联盟11月底完成审批年底之前挂牌成立 大连市长谭成旭调任鞍钢集团董事长姚林已调任中铝 世界军运会大幕拉开人民日报:为各国选手喝彩 施一公所创公司申请上市有望跻身十亿富豪 16省空降“金融副省长”:角色堪比“救火队长” 医疗器械企业收入将破万亿北上深居创新项目申请前3 新能源汽销连续三月下降锂电池上下游巨头业绩分化 第3代杂交稻首测亩产破1千公斤与前两代有何区别 花旗:小米集团重申买入评级目标价13港元 海康威视三季报:存货大幅上升部分供应商恢复供货 中国中医科学院院长:把中医药继承好发展好利用好 摩根大通CEO戴蒙:Libra是一个永远不会实现的好主意 美媒:普京又赢了俄土就叙利亚北部达成新协议 10月24日上市公司晚间公告速递 乐山帮的振静股份资本局:多名自然人股东大涨前潜伏 9月挖掘机销量高歌猛进市场普遍较为乐观 赛晶电力电子10月16日耗资19.22万港元回购20.6万股 雅虎宣布逐步关闭雅虎群组网站:永久删除所有内容 男子因下车问题暴打公交司机车辆失控撞上护栏 关键产品全部国产化北斗卫星不再被美企卡脖子 万圣节要来了美博物馆发起最恐怖娃娃投票(图) 欧理会主席图斯克:建议欧盟接受英国的延期脱欧请求 国考报名通过数破77.36万退休潮推动公务员需求上涨 韩国艺人雪莉离世“恶评”仍在 法国南部洪灾致3人死埃罗省雨量破50年记录 英大证券原董事长吴骏履新英大信托总经理 国资委谈央企“走出去”:全年营业收入5.4万亿元 北向资金净流入17.39亿元中国平安净买入5.04亿元 女医生遇刺身亡书记省长批示 美媒:中新加强版防务协议意义重大 梁建章孙洁联合发文:中国应放宽签证政策提升入境游 歌尔股份收关注函:说明回购计划动机 快讯:文化传媒概念股早盘走强博瑞传播直线涨停 张朝阳:以前想当名人现在想成优秀的管理者(视频) 外媒:土耳其一架民航教练机坠毁尚无伤亡情况 科大讯飞刘庆峰:AI将更加返璞归真解决刚需应用 医药股直线拉升陇神戎发涨停 发行渠道拥挤基金公司花式“赛马” 秦始皇陵控制带要建酒店引热议官方:不在保护区 期指高开低走IH跌0.55% 俄国防部:美通过走私叙利亚石油获利 澳大利亚水价疯狂飙升农民忧保不住作物破产 最高检:食品药品安全形势严峻三部门启动专项行动 特斯拉计划2020年生产电动卡车Semi:续航提升至966km 土俄协议后永久停火特朗普来抢功了 工信部:前三季度工业经济运行保持在合理区间 午后名博看市:调整结构还不够只差最后这一脚 FF计划明年一季度前融资8.5亿美元在中国寻合资伙伴 密码法草案二审增加密码“安全风险评估”机制 被特朗普批比IS更恶劣库尔德工人党“坐不住了” 美国10月制造业PMI初值51.5好于预期 中国寻求反制制裁是否影响中美两国磋商?外交部回应 印度男子欲营救3米长蟒蛇不料遭蛇瞬间“锁喉” 明年北京中考下月6日网报积分落户人员子女可报 提前备货加大科研海康威视三季度进一步复苏 比尔·盖茨大女儿男友曝光:已互见家长疑好事将近 韩国称俄军机进入其“防空识别区”韩出动F15K拦截 韩国央行处于宽松模式引发对实施QE的猜测 乌鸦看到尾巴就要揪一下,真的是因为嘴欠吗? 为对抗烟霾马来西亚开出89张罚单展开23项调查 国际锐评:对话合作还需进一步摒弃偏见 因旅客突发疾病厦航一国际航班紧急备降 美国一越野车被木头贯穿司机与死神擦肩仅受轻伤 “哈佛天才”被30万悬赏“睿康系”大厦将倾? 北京又添新地标:亚投行总部大楼宣告竣工(多图) 李茜:放宽外资险企准入将为资本市场带来更多新机会 致远互联中签号出炉共14644个 海信新机入网工信部:4850mAh电池+后置四摄 又是“躺赚”机会:单日11只可转债上会创年内新高 德国机构称部分婴儿奶粉检出矿物油残留 山东出台“十严”规定加强管控易制毒化学品 特斯拉市值530亿美元再超通用空头单日血亏14亿美元 这些地方有网友微信支付宝账号被封!公安部发文 河北邯郸民办校66名学生腹泻住院纪委监委介入 33岁扶贫干部核查贫困户信息途中遭遇车祸身故 网红袁岳凑科创板热闹:零点有数宣布开启上市辅导 iOS13省电教程关掉这8个功能iPhone多用3小时 谷歌之困:硬件支撑不足软件趋于封闭 我国拟在自贸区暂时调整实施道交法等六部法律规定 高盛三名投资银行家被控内幕交易牟取数千万美元 关于今天的鸡蛋涨停太合理了! 中国首枚液氧甲烷动力可重复使用运载火箭亮相 美国高层将出书揭白宫内幕曾匿名投稿批评特朗普 ST新光子公司遭20亿诉讼控股股东违规担保何时休 午评:沪股通净流入2.7亿深股通净流入15.53亿 河南南阳女子遭口罩男强行拖拽警方确定为绑架 英国首相约翰逊再迎尖峰时刻脱欧关键法案投票在即 中金:中国金茂重申跑赢行业评级目标价6.61港元 AMD“雷诺瓦”移动处理器曝光:45WR9来了 四维图新:前三季度实现净利2418万同比下降88.97% 融信付涉嫌非法经营支付结算业务涉案金额高达57亿 谭海鸣:预明年GDP实现6.1%增速降准可能在今年12月 想逢低做多亚马逊?当心飞刀! 15岁少年双眼2400度近视他的坏习惯或许你也有 工信部:9月底三家基础电信企业已开通5G基站8万余个